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BMD   Bone mineral density 
BMI   Body mass index 
BMP-2   Bone morphogenetic protein- 2 
CAD    Coronary artery disease 
Cbfa1    Core binding factor alpha 1  
CV   Coefficient of variation 
CVCs    Calcifying vascular cells 
CVD   Cardiovascular disease 
CIMT   Carotid intima media thickness 
eNO   endothelial nitric oxide 
eNOs   endothelial nitric oxide synthase 
FMD   Flow-mediated dilatation 
GSM   Gray scale median 
HDL   High-density lipoprotein 
hsCRP   high sensitive cross reacting protein 
ICAM-1   Intercellular adhesion molecule -1 
IL-1     Interleukin - 1 
IP-10    Interferon inducible protein -10 
LDL   Low-density lipoprotein 
M-CSF   Macrophage colony stimulating factor 
MCP-1  Monocyte chemoattractant protein 1 
MGP   Matrix Gla protein  
MMP-9   Matrix metalloproteinase-9 
NFκB    Nuclear factor kappa B 
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OCIF   Osteoclastogenesis- inhibitory factor = OPG 
OPG    Osteoprotegerin 
PAI-1    Plasminogen activator inhibitor 1 
PBMC   Peripheral blood mononuclear cells 
PDGF    Platelet derived growth factor 
SMCs    Smooth muscle cells 
sRANKL  soluble receptor activator for nuclear factor kappa B ligand 
TAT    Thrombin-antithrombin complexes 
TFPI (ag og ac)  Tissue factor pathway inhibitor antigen and activity 
TNF   Tumor necrosis factor  
TSP-1    Thrombospondin 1 
TRAIL  TNF-related apoptosis-inducing ligand 
Tromsø IV  The forth Tromsø Study (1994-95) 
Tromsø V  The fifth Tromsø Study (2001-02) 
VCAM-1   Vascular cell adhesion molecule-1  
VTE    Venous thromboembolism 
vWF   von Willebrand factor  





1.1 Atherosclerosis   
Cardiovascular disease (CVD) is the leading cause of death globally [1]. Atherosclerosis is 
the most frequent underlying cause of coronary artery disease, carotid artery disease and 
peripheral artery disease. Age, total cholesterol and LDL concentrations are risk markers for 
future cardiovascular events [2]. Nearly 100 years ago it was observed that rabbits fed a diet 
rich in eggs developed fatty lesions resembling atheroma [3]. Further dietary experiments 
showed that cholesterol and not other non-lipid constituents of  hen’s eggs caused the arterial 
lesions [3].  The combination of an individual’s genetic constitution and a high cholesterol 
diet induce changes in the vascular wall.  Even in the absence of other risk factors, elevated 
plasma cholesterol is sufficient to drive the development of atherosclerosis [4].  However, 
sudden death or myocardial infarction without warning symptoms is the first manifestation of 
coronary atherosclerosis in up to one-half of individuals [2]. Furthermore, many individuals 
who experience myocardial infarction have cholesterol concentrations at or below thresholds 
of 5.2 mmol/l (200 mg/dl) for total cholesterol and 3.4 mmol/l (130 mg/dl) for LDL 
cholesterol indicating that the importance of various risk factors differs between subjects [5].   
 
Atherosclerosis is a disease of large and medium-sized arteries nourished by lipid [4, 6, 7]. 
The early atherosclerotic lesions develop in a topographical pattern that strongly suggests 
involvement of hemodynamic forces in their pathogenesis [8]. Predilection sites are in areas 
where turbulent blood flow occurs.  Plasma molecules and lipoprotein particles extravasate 
through leaky endothelium.  
 
The response-to-injury hypothesis was introduced with the discovery of cytokines (cell 
hormones) and their receptors to explain the changes in the vessel wall associated with lipid 
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accumulation. Inflammation is considered to be involved in all cardiovascular diseases, 
including the earliest steps in atherogenesis.  Both in animal models and in humans, 
leucocytes are localized within the earliest lesions [9]. An atherogenic diet promotes the 
expression of selective surface adhesion molecules in endothelial cells such as vascular cell 
adhesion molecule -1 (VCAM-1).  VCAM-1 binds  monocytes and T-lymphocytes which 
typically are present in early experimental and human atheroma [9]. Increased expression of 
other leukocyte adhesion molecules such as intercellular adhesion molecule -1 (ICAM-1) 
have been reported in the presence of disturbed flow in the arteries [10].   Plasma cells and B-
lymphocytes may be present in adventitia nearby lesions [11], whereas neutrophils are present 
in trombosed coronary plaques, probably as a response to plaque rupture [12].   
 
The migration of leukocytes (monocytes and T-cells) into the intima is facilitated by 
chemoattractant molecules such as monocyte chemoattractant protein-1 (MCP-1) and IFN-
inducible protein 10 (IP-10)  [13, 14].  The monocytes differentiate to macrophages within the 
intima and take up atherogenic lipoprotein (modified LDL) via scavenger receptors [4].  The 
expression of scavenger receptors in macrophages are stimulated by inflammatory mediators 
such as macrophage colony stimulating factor (M-CSF) [9] which promotes the ingestion of 
lipids and in addition to MCP-1 promote the transition to foam cells [9]. Foam cells 
containing increasing amount of cholesteryl esters is a characteristic for both early (fatty 
streaks) and late atherosclerotic lesions. The scavenger receptors are not downregulated by 
increasing intracellular accumulation of modified LDL, leading to apoptosis and necrosis of 
the macrophages, and formation of a lipid-rich core within the atherosclerotic plaque.  In 
addition to degraded foam cells, atherogenic lipoproteins may accumulate within the intima 




As the lesion develops, the inflammatory process leads to release of fibrinogenic mediators 
that can promote proliferation of smooth muscle cells (SMCs) and production of a dense 
extracellular matrix [16].  Deposition of fibrous tissue characterize the more advanced 
atherosclerotic lesion [2], which may contribute to stabilize plaques, and thereby reducing the 
risk of plaque rupture and thrombosis [17].  The proliferation and secretion of  extracellular 
matrix proteins, including collagen by SMCs is stimulated by various growth factors, 
especially transforming growth factor-β and platelet-derived growth factor, [2] promoting the 
transition from a lipid-rich plaque to a fibrotic and, ultimately, a calcified plaque.   
 
The lipid-rich core of an atherosclerotic plaque is avascular and hypocellular.  Increased 
apoptosis lead to depletion of vascular smooth muscle cells and decreasing collagen 
supporting the plaque [18].   Furthermore, inflammatory mediators can inhibit collagen 
synthesis and evoke the expression of collagenases by foam cells within the intimal lesion 
[19, 20].  This leads to thinning of the fibrous cap, rendering it susceptible to rupture.  In 
human plaques, matrix metalloproteinase 9 (MMP-9) is catalytically active and may 
contribute to the dysregulation of extracellular matrix that leads to plaque rupture [21].  
Patients with stable coronary disease have increased serum levels of MMP-9 compared to 
controls [22], and during acute coronary syndromes plasma MMP-9 concentrations are 
increased 2-to 3-fold compared to controls [23].  A strong concordance between plaque size 
and morphology in different locations of the vasculature has been reported, indicating that 
systemic factors are important in the development [24].  Neovascularisation from the artery’s 
vasa vasorum represent another route for leukocyte entry into atherosclerotic lesions [25].  
Intraplaque haemorrhage from neovessels can generate thrombin which activates endothelial 
cells, monocytes/macrophages, SMCs and platelets [26]. Apoptosis contributes to 
redistribution of phospholipid on the cell surface and the formation of microparticles rich in 
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negatively charged phospholipid, which enhances tissue factor activity, and thereby the 
thrombogenicity of the lipid-rich core [27].  
 
The most common cause for artery thrombosis is plaque rupture where there is a defect or gap 
in the fibrous cap, thereby exposing the thrombogenic lipid-rich core followed by adhesion of 
platelets and activation of the coagulation system [4]. Key histological characteristics of 
plaques that have ruptured are a thin fibrous cap, abundant macrophages, and a low number of 
SMCs.  In acute coronary syndroms the culprit lesions are usually less calcified than plaques 
in patients with stable angina pectoris [28, 29].  In stable angina pectoris plaques often are 
associated with severe luminal narrowing because of constrictive remodelling.  In contrast, 
plaques responsible for acute coronary syndromes are usually relative large and characterized 
by expansive remodelling, preserving a normal lumen [24, 30]. Inflammatory activation rather 
than degree of stenosis renders the plaque vulnerable [20]. Rupture of a plaque is followed by 
thrombus formation which is the main cause of acute coronary events [31]. Tissue factor is 
expressed  in macrophages/foam cells in atherosclerotic plaques [32]. Tissue factor initiates 
blood coagulation by binding to factor VII/VIIa with subsequent proteolysis of factor IX and 
X leading to thrombin generation with subsequent fibrin formation and platelet activation [33, 
34]. The thrombogenicity of the plaque is associated with intramural tissue factor expression 
which is most pronounced in lipid rich plaques [35]. Whether plaque rupture leads to an 
occlusive thrombus depend on the balance between pro-coagulant and anti-coagulant factors.  
The formation of fibrin is the final step of
 
the coagulation cascade. The fibrinolytic system 
evokes the resolution of thrombi.  An imbalance between clot-dissolving enzymes and their 
endogenous inhibitors, primarily plasminogen  activator inhibitor-1 (PAI-1), may impair 





1.2 Vascular calcification 
Calcification is a common feature of atherosclerotic plaques. Accumulating evidence suggest 
that atherosclerotic calcification shares features with bone calcification, a process which is 
carefully regulated [37]. Calcification of arteries may be localized in the media or intima. 
Media calcification occurs independently of atherosclerosis and is observed frequently in end-
stage renal disease [38], diabetes mellitus [39], hypervitaminosis D [40] and in Mønkebergs’s 
sclerosis [41].   
 
Several models of intimal arterial plaque calcification have been proposed. 1; The passive 
model of arterial calcification postulates that arterial mineral deposition occurs when 
inhibitors are not able to prevent the precipitation [42].  2; The active osteoblast-like arterial 
cell model: Pluripotent arterial cells called calcifying vascular cells (CVCs) are colocalized 
with bone related proteins and transcriptional factors such as bone morphogenetic protein- 2 
(BMP-2) and core binding factor alpha 1(Cbfa1) in atherosclerotic plaques [43, 44].  
According to this model matrix Gla protein (MGP) inhibits calcification and Cbfa1 promotes 
differentiation of pluripotent arterial cells into an osteoblast-like cell  [45].  3; The “arterial 
OCL (osteoclast-like cell) model” suggests that arterial calcification is due to lack of activity 
of  OCL cells [46]. 
 
1.2.1 Osteoporosis and atherosclerosis 
Osteoporosis and atherosclerosis, especially vascular calcification, are commonly found 
together, mainly in elderly people and in individuals with autoimmune diseases [47-51].  An 
inverse association between bone mineral density (BMD) and calcification in the coronary 
arteries has been demonstrated, with the highest burden of calcified plaques in women with 
the lowest bone mineral density [52]. In patients with an acute ischemic stroke the presence of 
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hyperechogenic carotid plaques, the plaque type with highest level of vascular calcification,  
was an independent marker for osteoporosis [53].  In the Tromsø Study (n=5269) low bone 
mineral density (BMD) was associated with increased risk of echogenic atheroscerotic 
plaques of the right carotid artery [54].  A possible hypothesis for coexistence of osteoporosis 
and cardiovascular disease might be common risk factors, such as age, hypertension, diabetes 
mellitus, smoking, and hormonal modifications [53]. Oestrogen deficiency, abnormalities of 
vitamin D metabolism, and lipid oxidation in a common pathogenetic pathway for the two 
disorders have been implicated [38], but the underlying mechanisms that operate in bone 
metabolism and vascular homoeostasis have not been fully defined.  
 
1.3 OPG and RANKL 
Osteoprotegerin (OPG), receptor activator of nuclear factor κB ligand (RANKL) and the 
cytokine network they are part of, have been proposed to represent the long sought link 
between the skeletal system and the cardiovascular system [47].   
 
OPG was first identified in 1997 by several groups [55-58]. OPG was reported to be central in 
the regulation of bone turnover by inhibition of osteoclastogenesis, and OPG was 
alternatively termed osteoclastogenesis- inhibitory factor (OCIF) [59].  The mouse and human 
OPG proteins are 85% and 94% identical to the rat protein, respectively, indicating that the 
OPG gene has been highly conserved throughout evolution [55].  Human milk contains OPG 
at a level which is 1000- fold higher than in serum and it has been suggested that it might be 
of importance for bone mineral density and the immunological system of the child [60]. 
Possible sources for OPG are suggested to be both cells in milk, and mammary epithelial cells 
[60].  OPG is a secreted glycoprotein consisting of 401 amino acids, 21 amino acids is a 
signal peptide resulting in a mature form of 380 amino acids containing seven domains [55]. 
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The N-terminal region consists of four tandem cysteine-rich TNFR motifs, and the C- 
terminal half contains a heparin binding region [55]. The synthesized 55-62 kDA monomer is 
converted to a disulfide-linked homodimeric glycoprotein and secreted [55].  The heparin 
binding domain is involved in the formation of  homodimers [61]. OPG has no 
transmembrane domain and is in this respect an atypical member of the TNF receptor family. 
Transcripts of OPG have been detected in several murine tissues including liver, lung, heart, 
kidney, stomach, intestines, skin and the skull [55].  In humans the highest expression is in the 
lung, heart, kidney and placenta [55].  The wide tissue distribution of OPG suggests that this 
molecule has functions in addition to bone turnover.   
 
Overexpression of OPG in mice led to osteopetrosis  and splenomegaly (increased 
hematopoiesis), whereas no other abnormalities were found [55].  OPG knockout mice 
suffered from severe osteoporosis and vascular calcification [62].  In vitro,  recombinant OPG 
blocked osteoclastogenesis, and the N-terminal portion of  OPG containing the TNFR-like 
domain was necessary and sufficient to do so [55].   This effect was due to binding of OPG to 
RANKL on the surface of osteblasts, thereby preventing the binding of RANKL to its 
receptor RANK on precursors of osteoclasts [59].  RANKL is necessary for the maturation 
and activation of osteoclasts and is expressed on osteoblastic and stromal cells [59, 63]. The 
dimeric form of OPG exhibits a much higher affinity (two or three log) for RANKL than the 
monomeric form and also higher heparin-binding capacity [64].  RANKL exist either as a 
type II membrane protein or as a soluble protein [65]. Two receptors for RANKL have been 
indentified; soluble OPG and transmembrane RANK  [63, 65]. RANKL
-/-
 mice showed severe 
osteopetrosis and a defect in tooth eruption, and completely lacked osteoclasts [66]. 
Furthermore, early differentiation of T and B lymphocytes was disturbed and they lacked all 
lymph nodes, but had normal splenic structure and Peyer's patches. Thus, RANKL is a 
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regulator of lymph-node organogenesis and lymphocyte development, and is an essential 
osteoclast differentiation factor in vivo [66]. 
 
After binding of RANKL to RANK, intracellular signal transduction pathways such as 
mitogen-activated protein kinases (MAPKs) and nuclear factor kappa B (NFκB) are activated 
[65, 67]. Moreover, RANKL significantly stimulates monocyte chemotaxis via activation of 
phosphatidylinositol 3-kinase, phosphodiesterase, and Src kinase. The migration is inhibited 
by OPG [68]. Furthermore, OPG seems to regulate the interactions between T cells and 
dendritic cells. Dendritic cells isolated from OPG
-/-
 mice more efficiently present antigen in 
vitro and the release of inflammatory cytokines are enhanced when stimulated with bacterial 
products [69]. Thus, OPG seems to  downregulate  the immune response by decreasing 
dentritic cell survival [70]. 
 
1.4 OPG and TRAIL 
OPG can also stimulate cell survival by binding TNF-related apoptosis-inducing ligand 
(TRAIL).  TRAIL is also a member of the TNF family, it is a type II transmembrane protein 
and transcripts are detected in many human tissues [71].  TRAIL induces apoptosis in a wide 
variety of cells and tumour cells are more sensitive than non-malignant cells [71-73]. OPG 
produced by monocytes within tumours may be involved in survival of several tumour cell 
types [74-76].  Many tumour cell lines also express OPG [74, 77, 78], and in vitro studies 
indicate that OPG may act as a survival factor for tumour cells from both solid tumours [74, 
78] and haematological malignancies [79].  Inactivation of the tumour suppressor gene p53 
leads to increased secretion of OPG from endothelial tumour cells [80].  Furthermore, a pro- 
angiogenic effect of OPG by formation of cord like structures and networks has been shown 
[73].  Several studies have demonstrated that OPG can promote endothelial cell survival.  A 
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study by Pritzker et al suggested that inhibition of TRAIL was involved [81], however, others 
have proposed that other mechanisms are involved because TRAIL was reported to be absent 
from endothelial cell cultures [73, 82].  Recently, it was reported that the binding of OPG to 
TRAIL is in the same order of magnitude as the binding of OPG to RANKL [83].  
 
1.5 OPG and the skeletal system 
As mentioned, RANKL is necessary for the maturation and activation of osteoclasts and is 
expressed on osteoblastic and stromal cells [59, 63]. In patients with primary 
hyperparathyroidism, a condition associated with increased bone destruction, the ratio of 
RANKL/OPG expression within the bone microenvironment decreased after 
parathyroidectomi [84].  As increased osteoclast activity is observed in patients with 
osteoporosis, metastases and rheumatoid arthritis, the OPG/RANKL/RANK system appears 
to be a potential therapeutic target for bone diseases [85]. One single dose of recombinant 
OPG injected subcutaneously in postmenopausal women decreased bone turnover [86].  In 
mice with osteolytic sarcoma cells injected intramedullary, OPG treatment stopped further 
bone destruction and reduced ongoing and movement-evoked pain [87].  In humans with 
multiple myeloma with osteolysis and patients with bone metastases from breast carcinoma, 
bone resorption measured by urinary N-telopeptide of collagen decreased after one injection 
of recombinant OPG [88]. A potential concern with the use of OPG was development of anti-
OPG antibodies and that binding of OPG to TRAIL might interfere with a natural defense 
mechanism against tumourgenesis [89].  Denosumab is a human monoclonal antibody to 
RANKL. Osteoporotic postmenopausal women treated every 6 months for three years had 
reduced risk of vertebral, nonvertebral, and hip fractures compared to the placebo group [90].  
Denosumab treatment in men with prostate cancer treated with androgen blockade was also 
associated with increased bone mineral density [91].  
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1.6 OPG and the vascular system 
Expression of OPG has been observed in the heart, arteries and veins [92].  OPG is expressed 
in both endothelial cells and SMCs. In vascular SMCs TNFα, IL-1β, basic fibroblast growth 
factor (bFGF), platelet derived growth factor (PDGF) and angiotensin II are reported to 
increase the expression of OPG [93, 94]. SMCs has recently been suggested to be the main 
source of circulating OPG [95].  In endothelial cells, OPG expression is stimulated by TNFα, 
IL-1α, IL-1β, and  activated integrin αvβ3 [93, 96-98].  For some growth factors the expression 
of OPG is increased by activation of the transcription factor NF-κB, however,  PDGF 
mediated expression of OPG in smooth muscle cells was found to be independent of NF-κB 
[94], suggesting that alternative mechanisms exist for OPG expression.  
  
At the protein level OPG is localized in endothelial cells within the secretory granules, 
Weibel-Palade bodies (WPB) [99, 100].  Von Willebrand factor (vWF) and the adhesion 
molecule P-selectin are colocalized with OPG within the WPB.  vWF is considered to be a 
marker of endothelial dysfunction [101, 102]  that performs 2 main functions in haemostasis: 
it mediates platelet adhesion to the injured vessel wall, and it carries and protects coagulation 
factor VIII.  OPG was associated with vWF both within the WPB and in human serum and 
plasma [99, 100].   The interaction between OPG and vWF  is located to the A1 domain of 
vWF [100].  This domain can bind to GPIbα, collagen, heparin and sulphatides [103].  
Recently, it was reported that OPG is also colocalized with vWF in the alpha granules of 
human platelets [104].  
 
Risk factors for atherosclerosis, such as hypertension, smoking, hypercholesterolemia and 
diabetes, are associated with endothelial dysfunction leading to a pro-inflammatory and pro-
thrombotic phenotype of the endothelium [105].  As mentioned above, OPG is up-regulated 
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by pro-inflammatory cytokines in vascular smooth muscle cells and endothelial cells [94, 96, 
97].  RANKL has been reported to promote endothelial cell survival [106] and  to activate 
nitric oxide synthase pathways in endothelial cells [97],  whereas pre-incubation with 
recombinant OPG neutralized the activation [97].  Decreased NO (nitric-oxide) production is 
involved in the clinical course of  cardiovascular disease (CVD) and is reported to be a key 
feature which precedes vascular alterations [105].  Furthermore, OPG has been shown to 
induce the expression of  ICAM-1, VCAM-1 and E-selectin on endothelial cells and to 
promote leukocyte adhesion [82, 107]. An abnormal increase of leukocyte adhesion to 
endothelial cells is considered an early step in endothelial cell dysfunction [105].    
The inflammatory marker CRP predicts myocardial infarction, stroke and vascular death in a 
variety of settings [108].  CRP has been shown to down-regulate the production of endothelial 
nitric oxide synthase (eNOS), to induce the production of cellular adhesion molecules, to 
inhibit angiogenesis and to promote apoptosis [108, 109]. Thus, in cell cultures, OPG and 
CRP share some features, however, in contrast to CRP, OPG has been shown to promote 
survival of endothelial cells [73, 81, 98],  suggesting a possible role in maintaining 
endothelial integrity.  
 
The OPG/RANKL system; expression in atherosclerosis and cardiovascular disease  
OPG is considered to neutralize the effect of RANKL.  Both animal studies and studies in 
humans indicate that RANKL/RANK could be mediators in atherogenesis and plaque 
destabilization. Dhore et al demonstrated presence of OPG and RANKL in SMCs in non-
diseased aortas from humans. In plaques, RANKL could only be demonstrated
 
in association 
with the extracellular matrix surrounding calcium
 
deposits. High expression of OPG was
 
seen 
in inflammatory cells present in plaques. A regulatory role of these proteins was suggested 
not only in osteoclastogenesis, but also in atherosclerotic calcification [37]. Golledge and co-
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workers studied endartherectomy samples removed from patients with recent (within 6 
weeks) focal neurological symptoms or no previous symptoms and demonstrated higher 
expression of OPG in carotid atherosclerotic plaques in symptomatic subjects than in non 
symptomatic subjects.  Furthermore, treatment with the angiotensin II blocker irbesartan 
reduced the OPG secreted by explants [110].    
 
In mice RANK and RANKL are only expressed in calcified plaque and not in normal arteries 
[111], indicating that the calcification process itself could up-regulate RANK and RANKL 
expression and signaling.  In apoE
-/-
 mice strong RANK and OPG immunoreactivity was 
observed in SMCs and endothelium of nonatherosclerotic areas, whereas RANKL was not 
detected [112]. Stronger immunoreactivity for both OPG (adjacent to foam cells) and RANK 
(more evenly distributed in lesions) was demonstrated.  Within lesions, RANKL staining was 
present in areas rich in T-cells and macrophages [112].  More prominent staining for OPG, 
RANKL and RANK was reported in more vulnerable plaque phenotype partly due to 
increased INF-γ [112].  
In patients with unstable angina pectoris increased gene expression of RANKL in T cells and 
RANK in monocytes were demonstrated compared to healthy controls.  OPG transcripts were 
not detected in T cells [112]. In PBMCs from patients with stable angina pectoris undergoing 
PCI the expression of  RANKL increased significantly 4 hrs after PCI compared to baseline.  
No significant change in RANK was detected [112].  In thrombus material from patients with 
ST elevation myocardial infarction, strong OPG, RANKL and RANK immunoreactivity in 
monocytes/macrophages and areas with CD41 positive platelets was reported [112].   
In patients with unstable angina, RANKL increased the release of monocyte chemoattractant 
protein 1 (MCP-1) from PBMC, in contrast no significant effect was observed in patients with 
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stable disease and controls.  RANKL had no effect on IL-8, TNFα and MIP-1α in either 
patients or controls [112]. 
Matrix metalloproteinases (MMPs) are a class of
 
proteins thought to influence the 
composition and thereby the vulnerability of plaques, rendering them susceptible to plaque 
rupture and thrombosis. In patients with acute coronary syndrome increased expression of 
MMP-9 and MMP-9/TIMP-1 ratio has been reported in debris from coronary plaques 
compared to plaques from patients with stable angina [113]. OPG treatment induced increased
 
levels of MMP-9 in macrophage-like cells as well as
 





was a potent inducer of MMP-9 activity in bone marrow-derived
 
macrophages [114]. In vascular SMCs, but not in macrophages, RANKL increased total 
MMP activity (MMP-1,-2,-7,-8,-9,and-13) [112].  OPG increased the RANKL effect on MMP 
activity in SMC at molar ratios of 0.5 and 3 (molar ratio in serum ≈ 100) [112].  At very high 
concentrations of OPG, OPG alone induced MMP activity in vascular SMCs [112].    
 
OPG and thrombosis                                                                                                           
Limited data on OPG and coagulation factors are available. However, in a study in women 
with previous gestational diabetes, no significant association between OPG and vWF, PAI-1 
and fibrinogen was reported [115].  In a case-control study in young survivors of myocardial 
infarction, we found no significant associations between OPG and factor VIIa, factor VIIc, 
fibrinogen, tissue factor pathway inhibitor antigen (TFPIag), TFPIac, and thrombin- 
antithrombin complexes (TAT) measured 1-4 years after acute myocardial infarction in  
patients or in controls [116]. Zannettino et al showed that OPG is able to bind vWF reductase, 
and thrombospondin 1 (TSP-1). They speculated that this may aid in tethering the ultra large 
vWF multimers at the site of vascular injury, thereby promoting thrombus formation [99].  
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Some studies indicate that subjects with CVD have increased risk of venous 
thromboembolism (VTE) and vice versa [117, 118].  Risk factors responsible for this 
association are poorly understood. In the Physicians’ Health Study, hypertension, elevated 
cholesterol, diabetes, and smoking were associated with increased rates of CHD and stroke, 
but had no association with VTE. Conversely, higher BMI was more strongly associated with 
risk of VTE than of either CHD or stroke, and taller men had a significantly increased risk of 
VTE, but a lower risk of CHD [119]. A link between elevated OPG levels and occurrence of 
both venous thrombosis and bleeding was reported in patients with the chronic 
myeloproliferative disease polycythaemia vera [120].  One unit change in OPG was 
associated with 33% (p=0.03) increased risk of venous thrombosis and with 37% (p=0.013) 
increased risk of bleeding in a retrospective analysis. OPG was also related to the 
development of the combined outcome of venous thrombosis and bleeding in a prospective 
analysis [120].  
 
1.7 OPG and other diseases associated with cardiovascular disease 
Serum levels of OPG are increased in subjects with diseases characterized of inflammation 
and associated with increased risk of atherosclerosis and cardiovascular death.   
 
OPG in renal failure 
Theoretically, reduced elimination of OPG could be involved in patients with renal failure.  
However, studies in rats showed that 
125
I-labelled protein was rapidly and predominantly 
distributed to the sinusoids of the liver after  intravenous injection [121]. The hepatic uptake 
was partly regulated under a saturable process, pre-dosing with sulfated glycans such as 
dextran sulfate and heparin markedly inhibited the uptake [121].  In patients with renal failure 
OPG is associated with mortality. In subjects undergoing hemodialysis elevated plasma OPG 
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predicted all-cause mortality and cardiovascular mortality after adjustment for cardiovascular 
risk factors. OPG was a particularly strong predictor for mortality in patients with increased 
CRP [122]. In patients (without diabetes) followed for 8 years after renal transplantation, 
serum OPG measured within 10 weeks post transplant, was independently associated with all-
cause mortality and cardiovascular death [123].  
 
OPG and diabetes mellitus 
In subjects with diabetes mellitus, Browner et al reported increased serum OPG [124], a 
finding confirmed in several studies.  Anand and coworkers have published two prospective 
studies in patients with type 2 diabetes mellitus. In the first study, plasma OPG was 
significantly elevated in patients (n=510) with increased coronary artery calcification both in 
crude and adjusted analyses. In a multivariable model, only coronary artery calcification score 
was an independent predictor for cardiovascular disease and mortality [125].  In their second 
study in 390 subjects without cardiovascular symptoms, OPG was significantly associated 
with increased coronary artery calcification score in univariable analysis, but not in 
multivariable analysis [126].  
 
OPG and heart failure 
In 234 patients with acute myocardial infarction complicated with heart failure (LVEF < 
35%) serum OPG remained elevated compared to controls during 27 months of follow up,  
and OPG at baseline was associated with adverse outcome and remained an independent 
predictor for cardiovascular events and mortality [127].  The same research group has shown 
that serum OPG increases in patients with heart failure, irrespective of the etiology of heart 
failure [128].  In men with nonischemic dilated cardiomyopathy, plasma TRAIL were 
elevated compared to controls and positively correlated with left ventricular end-diastolic 
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diameter. In this study, plasma OPG did not differ between patients and healthy controls. In 
endomyocardial biopsies, TRAIL and OPG protein were detected by immunohistochemistry, 
but not in controls. In patients, TRAIL mRNA was upregulated in peripheral blood 
lymphocytes.  OPG mRNA was up-regulated in the myocardium, possibly representing a 
compensatory mechanism to limit systemic activation of TRAIL in patients with congestive 
heart disease [129]. 
 
Rheumatic disease, CVD and OPG 
OPG concentrations were increased in patients with rheumatoid arthritis and associated with 
inflammation [130]. OPG concentrations were higher in patients with long-standing 
rheumatoid arthritis and in this group associated with coronary-artery calcification 
independently of cardiovascular risk factors and disease activity [130]. In patients with 
inflammatory rheumatic diseases and coronary artery disease (CAD) increased plasma levels 
of markers of endothelial cell activation such as VCAM-1, vWF and OPG was found 
compared to patients with CAD without inflammatory rheumatic disease.   Acute coronary 
syndrome was a significant predictor of OPG in the group with inflammatory rheumatic 
disease.  OPG and several other markers of inflammation, but not lipids, predicted CAD in 
patients with inflammatory rheumatic disease, in contrast to the group with CAD alone [131].   
 
1.8 Ultrasonographic examination for carotid artery plaque assessment  
The carotid arteries are readily accessible for ultrasonographic examination, and it is a safe, 
low-cost method for the assessment of atherosclerosis, both in terms of the presence of 
plaques and plaque morphology.  It is based on two principles; high resolution B-mode 
imaging to visualize the arterial wall and any local changes, and Doppler flow studies to study 
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blood flow and changes in blood flow velocity associated with stenosis or the absence of flow 
associated with occlusion.  A brief description of B-mode imaging will be given.  
 
Ultrasound waves are partly absorbed by the tissue and partly reflected. In the ultrasound 
transducer an oscillating piezoelectric element sends pulses of ultrasonic waves into the 
tissue.  In a certain period after the transmission of waves, the transducer is able to receive 
reflected ultrasound and convert it to electrical signals, which are processed into a two-
dimensional grey-scale image by a computer.  The acoustic impedance, which is defined as 
the product of the density of the tissue and the velocity of the sound, determines how much of 
the emitted ultrasound that are reflected. The higher the difference in density between the 
tissue layers, the more energy is reflected and the brighter will the object appear on the B-
mode image (B; brightness).  Fibrous and calcified tissue will appear bright, whereas moving 
blood cells will appear black. 
 
Examination of the carotid arteries with ultrasound is a more sensitive method for detecting 
carotid plaques than angiography, and there is a high correlation between plaque in the carotid 
arteries and other vascular territories such as the coronary arteries [132]. The earliest visible 
change in the carotid artery associated with atherosclerosis is an increase in the intima media 
thickness.  The atherosclerotic process mainly involves intima of arteries; however, it is not 
possible to distinguish well between the intima and media by ultrasound.  Carotid intima 
media thickness (CIMT),  measured precisely and noninvasively by B-mode ultrasonography, 
is a  marker of early atherosclerosis [132] associated with cardiovascular risk factors such as 
age, smoking, hypertension, obesity, dyslipidaemia, diabetes and metabolic syndrome [133-
135].  CIMT increases nearly linearly with age [135], and has also been shown to predict 
cardiovascular events both in the myocardium and brain [136, 137]. Evaluation of plaque 
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burden can be done by several methods. The simplest method is to determine whether plaques 
are present or not and to report the number of plaques.  Secondly, the thickness of each plaque 
can be measured; a total atherosclerotic score can be calculated by summarizing the thickness 
of all plaques detected.  Thirdly, the area of plaques can be calculated offline by tracing 
around the perimeter of each plaque on stored B-mode images with a cursor. Finally the most 
accurate method would be a three dimensional assessment which can be done by computer 
tomography or magnet resonance imaging.  However, it is an expensive method and not well 
suited for larger epidemiological studies.  
 
Plaque morphology can be assessed by how the carotid plaques appear on the B-mode image.  
Based on echogenicity, defined as reflectance of the emitted ultrasound signal, Gray-Weale et 
al proposed four categories of plaque echogenicity; echolucent, predominantly echolucent, 
predominantly echogenic and echogenic [138]. The echolucent plaques are lipid rich, whereas 
the echogenic plaques contain more dense fibrous and calcified tissue.  Histological studies of 
endarterectomy samples have shown a high concordance with plaque morphology assessed by 
ultrasound [138-140]. 
 
Plaque morphology in terms of echogenicity may also be assessed by objective measurements 
by recording all examinations and measurements of plaques. The echogenicity of digital 
plaque images may be expressed as a continuous variable on a grey scale, averaged for all 
pixels in the picture [141].  The inter-observer reproducibility of GSM analysis is good [141-
144].  Echolucent plaques with low GSM score are lipid rich whereas echogenic plaques 
contain more fibrous tissue and calcium.  Examinations of carotid endarterectomy samples 
have shown a high concordance between GSM (included colour mapping) and the histological 
picture [145, 146].  
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2. Aims of the study  
The overall aim of the project was to study the relation between serum OPG and carotid 
atherosclerosis as assessed by CIMT, plaque echogenicity, novel plaque formation, plaque 
progression, and cardiovascular diseases and mortality. 
Specifically, the aims of the subprojects were to study: 
 
1. The association between serum concentrations of OPG and carotid plaque echogenicity in 
subjects with carotid plaques. 
2. The association between OPG serum concentration and carotid intima media thickness 
(CIMT), a surrogate marker for early atherosclerotic disease, in a large population-based 
study with a wide age span of participants.   
3. The association between OPG and cardiovascular risk factors, and the impact of serum 
levels of OPG and sRANKL on de novo atherosclerotic plaque formation and plaque 
growth in the right carotid artery during seven years of follow-up, in a general population. 
4. The association between OPG and cardiovascular disease (myocardial infarction, ischemic 
stroke, hemorrhagic stroke) and mortality (total, cardiovascular and non-vascular 
mortality) during twelve years of follow-up in a population-based cohort study.  
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3. Study populations and methods 
Description of study design, inclusion and exclusion criteria, laboratory and clinical 
measurements and statistical methods are given in detail in the separate papers.  The present 
chapter gives a brief description of the study populations and discusses briefly some 
epidemiological and statistical aspects.   
 
3.1 The Tromsø Study and participants 
The Tromsø Study is a single centre prospective follow-up study of the population of Tromsø, 
Norway  The studies have been carried out by the Department of Community Medicine at the 
University of Tromsø, in collaboration with the Norwegian Institute of Public Health 
(formerly the National Health Screening Service), the University Hospital of Northern 
Norway (UNN) and Tromsø City Council. The main focus of the Tromsø Study has been on 
cardiovascular disease.  The first survey was carried out in 1974 (Tromsø I), followed by 
surveys in 1979-80 (II), 1986-87 (III), 1994-95 (IV), 2001-02 (V) and 2007-08 (VI).                                                                                            
 
The participants in paper 1 were recruited from Tromsø V and the participants in paper 2, 3 
and 4 were recruited from Tromsø IV. Participants included in the study reported in paper 3 




 survey consisted of two screening visits 4-12 weeks apart.  All registered inhabitants 
of Tromsø 25 years or older were invited to the first screening visit. The invitation letter also 
contained a questionnaire about cardiovascular risk factors and disease and declaration of 
consent (Appendix A).  Of 35 443 invited, 27 168 (76.6%) attended the first visit.  To the 
second visit (phase 2) all subjects aged 55-74 years and 5-10% samples in the other 5-year 
birth cohorts were invited.   The total number invited to the second visit was 8732 subjects of 
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whom 6889 (78.9%) attended.  A more comprehensive examination, including ultrasound 
examination of the right carotid artery was performed in 6727 subjects of those who attended, 
i.e. 77.0% of the eligible population.  The participants were given a second questionnaire 
covering such issues as dietary habits, use of drugs, life style factors etc (Appendix A).  A 
shorter questionnaire was used for participants older than 70 years (Appendix A).    
 
Paper 1: Participants for this case-control study was recruited from Tromsø V (2001-02) 
Subjects included were randomly selected among 56–80 years old participants who had one 
plaque or more in the right carotid bifurcation or internal carotid artery at the screening visit 
with a plaque thickness of ≥2.5mm and plaque morphology classified as echolucent (grade 1) 
or echogenic (grade 4) according to the Gray–Weale criteria [138]. Persons in the same age 
groups without plaques in their carotid arteries were used as controls.  As only the right 
carotid artery was examined at the screening visit, a new ultrasound examination including 
both carotid arteries was performed.  
 
Paper 2: All participants in this cross sectional study had taken part in the carotid ultrasound 
examination in Tromsø IV. Valid measurements of CIMT were available in 6677 subjects. 
Fifty-seven persons were excluded due to lack of written consent to future medical research. 
Subjects with frozen serum samples available for OPG measurement were included (n=6516).    
 
Paper 3: Subjects examined by carotid ultrasound both in Tromsø IV and V were included.  
Of the 6727 examined with carotid ultrasound in Tromsø 4, 956 subjects did not attend 
Tromsø V, 110 attended, but were not examined with ultrasound due to logistic problems, 271 
subjects had moved from Tromsø, and 532 had died.  Serum samples for OPG measurements 
were lacking for 100 subjects, and 219 subjects were excluded due to low ultrasound image 
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quality. Consent was lacking for 19 subjects. Thus, 4520 subjects with valid measurements 
were included in the study.  
 
Paper 4: Eligible subjects were those who attended both the first and second visit of Tromsø 
IV (n=6899). Subjects not officially registered inhabitants of the municipality of Tromsø at 
baseline (n=13), without valid measurement of OPG (n=87), with a known history of 
myocardial infarction (n=378), ischemic stroke (n=79) or both (n=20) at baseline, and 
subjects without valid written consent (n=57) were excluded from the cohort participating in 
Tromsø IV phase 2, leaving 6265 subjects who were followed up from the day of enrolment 
in 1994/95 to 31
st
 of December 2005.  
 
3.2  Ultrasound examination 
The ultrasound methods are described in detail in the papers. The protocol for the ultrasound 
procedures is included in appendix B. The right carotid artery was scanned with the subject in 
the supine position with the head slightly rotated to the left. The ultrasound examinations in 
were carried out by three sonographers (different in each survey).  To standardize 
measurements the sonographers completed a 2-month training program.  As previously 
reported, the intra- and interobserver reproducibility on measurements of carotid intima-
media thickness, plaque occurrence, plaque thickness and plaque echogenicity was good in 
each of the study examinations [147, 148].  Subjects included in paper 1 underwent a repeated 
scanning of both the left and right carotid arteries.  
 
3.3  Biochemical analyses 
Non-fasting blood samples were collected from an antecubital vein and serum was prepared 
by centrifugation after one hour respite at room temperature. Serum aliquots were stored at -
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70 °C. OPG and sRANKL were analysed in thawed serum stored for 12 years. The analyses 
were performed on coded samples without knowledge of status regarding atherosclerosis in 
the carotid arteries by the person performing the assays. All samples were analyzed in 
duplicate. 
 
3.4 Clinical end points assessment 
In paper 4 we studied the relation between OPG measured at baseline and incident myocardial 
infarction, ischemic stroke, hemorrhagic stroke, total mortality, death of myocardial 
infarction, death of stroke and death of non-vascular causes during up to 12 years follow-up.  
Adjudication of hospitalized and out-of hospital events was performed by an independent 
endpoint committee and based on data from hospital and out-of hospital journals, autopsy 
records, and death certificates. The national 11-digit identification number allowed linkage to 
national and local diagnosis registries. Cases of incident myocardial infarction and ischemic 
stroke were identified by linkage to the discharge diagnosis registry at the University Hospital 
of North Norway (UNN) with search for ICD 9 codes 410-414 and 430-438 in the period 
1994-98, and thereafter ICD 10 codes I20-I25 and I60-I69. UNN is the only hospital in the 
area serving the Tromsø population. The hospital medical records were retrieved for case 
validation. Slightly modified WHO MONICA/ MORGAM criteria for MI were used and 
included clinical symptoms and signs, findings in electrocardiograms (ECG), values of 
cardiac biomarkers, and (when applicable) autopsy reports [149]. An ischemic stroke was 
defined according to the WHO definition [150]  only when CT or MRI scans had ruled out 
brain haemorrhage. Further, linkage to the National Causes of Death Registry at Statistics 
Norway allowed identification of fatal incident cases of myocardial infarction and ischemic 
stroke that occurred as out-of-hospital deaths, including deaths that occurred outside of 
Tromsø, as well as information on all-cause mortality. Information from the death certificates 
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was used to collect relevant information of the event from additional sources such as autopsy 
reports and records from nursing homes, ambulance services and general practitioners.   The 




4. Main results 
4.1 Paper 1 
Serum osteoprotegerin is inversely associated with carotid plaque 
echogenicity in humans.  
The purpose was to study the relation between serum OPG levels and plaque morphology in 
subjects with subclinical carotid atherosclerosis and controls. Participants were recruited from 
a population health study (Tromsø V) and OPG serum levels were compared in 29 persons 
with echogenic (fibrotic and/or calcified) carotid plaques, 30 persons with echolucent (lipid 
rich) plaques and 41 persons without carotid plaques. Computerized assessment of plaque 
echogenicity was done by use of the gray scale median (GSM).  
Participants with echogenic carotid plaques (defined as GSM above median, GSM >64.45) 
had lower serum OPG level (1.23 ng/ml; 1.02-1.48) (geometric mean; 95% CI) than persons 
with echolucent plaques (GSM ≤ 64.45) (1.76 ng/ml; 1.46-2.14) and those without plaques 
(1.89 ng/ml; 1.60-2.21). Both OPG and PTH were independently related to GSM. A 
significant linear trend for decrease in GSM across quartiles of OPG was found (p=0.003) 
which remained significant after adjustment for PTH and smoking.  
Thus, lower serum OPG levels in subjects with subclinical echogenic carotid plaques and an 
inverse relation between serum OPG and plaque echogenicity were demonstrated. The 





4.2 Paper 2 
Relation between serum osteoprotegerin and carotid intima media 
thickness in a general population – The Tromsø Study.   
CIMT, measured precisely and noninvasively by B-mode ultrasonography, is a marker of 
early atherosclerosis. Previous studies have reported conflicting results on the relation 
between serum OPG concentration and CIMT. The present study was conducted to 
investigate the relations between OPG, risk factors for cardiovascular diseases and CIMT in a 
large cross-sectional study including 6516 subjects aged 25-85 years who participated in a 
population based health survey.  CIMT increased significantly across tertiles of OPG after 
adjustment for traditional cardiovascular risk factors such as age, sex, smoking, total 
cholesterol, HDL cholesterol, CRP, BMI, systolic blood pressure, cardiovascular disease 
(CVD) and diabetes mellitus (p< 0.0001). There was a significant interaction between age and 
OPG (p=0.026).  Increasing OPG concentrations (per SD) reduced the risk of being in the 
uppermost quartile of CIMT (OR 0.52, 95% CI 0.30-0.88) in subjects < 45 yrs (n=444), 
whereas subjects ≥ 55 yrs of age (n=4884) had increased risk of being in the uppermost 
quartile of CIMT (OR 1.19, 95% CI 1.10-1.29) after adjustment for traditional CVD risk 
factors.  Thus, age has differential impact on the association between OPG and CIMT in a 
general population. The present findings may suggest that increased serum OPG does not 






4.3 Paper 3 
Serum osteoprotegerin, sRANKL and carotid plaque formation and growth 
in a general population – The Tromsø Study. 
Intervention studies in animal models suggest that osteoprotegerin (OPG) functions as an 
inhibitor or marker of atherosclerosis, whereas one prospective epidemiological study in 
humans indicated that OPG was an independent risk factor for progression of atherosclerosis. 
This study was undertaken to explore the association between serum levels of OPG, soluble 
RANK ligand (sRANKL) and carotid artery plaque formation and plaque growth.  The 
prevalence of carotid plaque and plaque area were assessed by ultrasonographic imaging at 
baseline and after 7 years follow-up in 2191 men and 2329 women who participated in a 
population-based study. OPG was significantly associated with atherosclerotic plaque burden 
and cardiovascular risk factors such as age, body mass index, blood pressure, total 
cholesterol, HDL cholesterol, HbA1c, fibrinogen at baseline, but not with sRANKL.  In 
subjects without plaque at baseline, OPG predicted plaque formation in crude analysis in both 
women and men, but not after adjustment for age and other atherosclerotic risk factors. OPG 
predicted plaque growth in women (+1.8 mm
2
, 0.6-3.0) (mean, 95% CI) per 1 SD increase in 
OPG (p=0.003), whereas no associations were demonstrated in men (0.1 mm
2 
(-1.3-1.4), 
p=0.93). Soluble RANKL did not predict plaque formation or plaque growth.                                   
OPG was an independent predictor of plaque growth in women, but not in men, suggesting 
sex specific actions of OPG in plaque growth. OPG was not associated with novel plaque 




4.4 Paper 4 
Serum osteoprotegerin is a predictor for incident cardiovascular disease 
and mortality in a general population – The Tromsø Study. 
Osteoprotegerin (OPG) concentration in serum is associated with the presence and severity of 
atherosclerosis, and predicts cardiovascular disease and mortality in high-risk populations.  
The present study was undertaken to investigate the association between serum OPG levels 
and risk of future myocardial infarction (MI), ischemic stroke (IS) and mortality in a general 
population.  Serum OPG was measured in serum samples from 6265 persons without prior 
cardiovascular diseases aged 25 to 84 years, who participated in a population health survey, 
The Tromsø Study, in 1994-95.  Incident MI, IS and mortality were registered from the date 
of inclusion until 31
th
 of December 2005.  Cox regression models were used to estimate crude 
and adjusted hazard ratios (HR; 95% CI) for clinical events. There were 575 MI, 284 IS, and 
824 deaths (146 deaths of ischemic heart disease, 78 deaths of stroke, and 600 deaths of other 
causes) during median 10.6 years of follow-up. Serum OPG concentrations (per SD (1.13 
ng/ml) increase in OPG) were associated with increased risk of MI (1.20; 1.11-1.31), IS (1.32; 
1.18-1.47), total mortality (1.41; 1.29-1.54), death of ischemic heart disease (1.35; 1.18-1.54), 
death of stroke (1.44; 1.19-1.75) and death of non-vascular causes (1.31; 1.22-1.41) after 
adjustment for traditional cardiovascular risk factors. No association was detected between 
OPG and incident hemorrhagic stroke (HR 1.02; CI 0.73-1.43).                                                        
Serum OPG was associated with future risk of MI, IS, total mortality, mortality of ischemic 
heart disease, stroke and of non-vascular causes independent of traditional cardiovascular risk 
factors. These findings suggest that serum OPG is a mediator and not merely a marker of 




5. General discussion 
5.1 Methodological considerations 
5.1.1 Measurements of OPG and RANKL 
The concentration of total OPG was analyzed by an ELISA assay (R&D Systems, Abingdon, 
UK) with mouse anti-human OPG as capture antibody. The assay detects both the monomer 
and dimeric forms of OPG, including OPG bound to its ligands. Biotinylated goat anti-human 
OPG and streptavidin horseradish peroxydase were used for detection. The OPG assay was 
performed according to the instructions by the manufacturer. The intra- and interassay 
coefficients of variation (CV) in our laboratory were 6.5% and 9.3%, respectively.  
 
The concentration of sRANKL was measured by a new, highly sensitive ELISA assay for free 
sRANKL with a detection limit of 0.02 pmol/L (ampli sRANKL human, Biomedica, Vienna, 
Austria). The analysis was performed according to the manufacturer’s instruction. The 
intra- and interassay CV for the RANKL assay were 9.3% and 15.0%, respectively.   
Despite using the most sensitive assay available for measurement of free sRANKL in serum, 
sRANKL was not detectable in 25.8% of serum samples and below the detection limit of  
0.02 pmol/l in 10.4% of samples. In a recently published study by Lieb et al, using the same 
assay from Biomedica, the concentration of sRANKL was below the detection limit in 25% of  
the samples [151].  Kiechl et al reported  high consistency in absolute
 
levels of serum 
RANKL and OPG in  3 assessments (1990, 1995,
 
and 2000) indicating long-term stability 
when stored at -70°C without any thawing-freezing
 
cycle [152]. In contrast, in EDTA plasma 
others have reported 9.5% and 56.5% decrease in sRANKL
 
compared to baseline when stored 
at -70 °C for
  
6 weeks and 6 months, respectively [153]. The OPG plasma concentration was 
reduced by 5.3% after 6 weeks and 19.7% after 6 months storage at -70 °C [153]. 
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Furthermore, compared to other anticoagulants, EDTA was the preferred anticoagulant in 
preparation of plasma [153].   
 
Undetectable free sRANKL in a large proportion of samples in our study may indicate that 
measurement of total RANKL might be favourable. The long storage time of blood samples 
might also be of importance.  Although a reduction in concentration during storage cannot be 
ruled out, OPG was above the detection limit in all samples. However, it is not likely that this 
introduced major bias as long as all samples were handled equally.   
Blood sampling took place from the morning until the afternoon and participants were not 
fasting.  We have previously shown in young normolipemic males that plasma OPG levels 
showed a modest, but significant decrease during the day compared to the plasma 
concentration at 8 am, and that it remained decreased throughout the following 12 h and 
returned to baseline values the next morning [154]. Others have reported that the circadian 
rhythm of OPG secretion was characterized
 
by higher daytime concentrations and a nocturnal 
decrease in post – and premenopausal women and in elderly men [155]. To study the effect of 
a meal rich in lipids, blood samples were collected in the fasting state and 4 hrs after ingestion 
of porridge (peak triglyceride concentration in serum appeared 4 hrs after the meal).  The 
standard meal was accompanied by a substantial increase in serum triglycerides from 
1.23±0.68 mmol/l in the fasting state to  2.23±1.37 mmol/l in the postprandial state (p<0.001) 
with only a minor decrease in serum OPG levels from 1.45±0.48 ng/ml in the fasting state to  
1.32±0.38 ng/ml in the postprandial state, a reduction  similar to that observed in young 
healthy males [154]. Thus, we do not think that non-fasting blood samples and various time 





5.1.2 Study design, bias and misclassification 
Two longitudinal cohort studies, one case-control study and one cross-sectional population-
based study are included in this thesis.  In cohort studies, the difference in outcome between 
exposed and nonexposed subjects are studied. Participants often need to be followed for a 
long time to accumulate sufficient person-time and end-points and thereby they are resource 
demanding. Bias has been defined as any systematic error in the design, conduct or analysis 
of a study that results in a mistaken estimate of an exposure’s effect on the risk of disease 
[156].   Cohort studies are vulnerable to selection bias, where the relationship between 
exposure and disease might differ in subjects participating compared to all that were eligible 
for the studies [157].  
In case-control studies diseased and non-diseased subjects are compared. This design is often 
used as a first step when searching for a cause of a disease and is very useful in rare diseases.  
Controls should be selected from the same population, i.e. the source population that gives 
rise to the study cases. Sometimes it is stressed that cases should be representative for all 
people with the disease and that controls should be representative for the entire non-diseased 
population. This can be misleading; a case-control study may be restricted to any type of case 
that may be of interest as long as it has a sound rationale [158].  A major concern in case-
control studies is that cases and controls may differ in characteristics or exposures other than 
the one that has been targeted for study.  One approach to handle this is to match the cases 
and controls for these characteristics.   In our case-control study (paper 1), no significant 
differences between the groups with regard to cerebrovascular risk factors, included prior 
cardiovascular disease, strengthen the results despite the low number of participants.  Recall 
bias is a problem in case-control studies where one or more characteristics studied are based 
on information from the participants.   To increase the power of a case-control study with few 
cases increasing the number of controls up to a ratio of 1 case to 4 controls may be done.  A 
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major limitation with traditional case-control studies is that it is not known whether the 
disease or condition studied preceded the changes observed in biological characteristics or 
that they were a result of the disease itself. This problem can be overcome by conducting a 
nested case-control study, i.e. a case-control study within a cohort where the temporal 
sequence of exposure and disease can be studied and recall bias is eliminated. This study 
design is less resource demanding than a cohort study.    
 
Cross-sectional studies can give information about associations.  However, it is not possible 
to establish a temporal relationship and this type of study may only be suggestive of a 
possible risk factor for a disease.  In cohort and nested case-control studies a temporal 
relationship between exposure and outcome may be found, increasing the possibility of an 
etiologic relationship.  However, observational studies cannot definitively examine whether 
biomarkers are causally related to a disease.   
 
Information bias can occur when obtained information about the subjects in the study is 
inadequate, so that the information regarding exposures and/or disease is incorrect.  When the 
gathering of data is inaccurate, subjects may be misclassified and thereby misclassification 
bias is introduced.  Misclassification might be differential or nondifferential.  Differential 
misclassification occurs when the rate of misclassification differs in the different study groups 
such as in e.g. case control studies where recall bias more often occur in cases than controls. 
Differential misclassification bias can lead to an apparent association that is false or an 
apparent lack of association that is false [156]. In nondifferential misclassification there is 
inaccuracy in the gathering of information in both cases and controls or exposed and 
unexposed subjects.  The effect of this misclassification is usually that the relative risk or 
odds ratio tends to be diluted, i.e. shifted toward 1.0.  Thus, an association is less likely to be 
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detected [156].   Although a high concordance between plaques in the carotid arteries and 
other vascular territories have been reported, screening of the left carotid artery as well as 
other vascular territories in our study (paper 3) would have given a more accurate assessment 
of plaque burden in each individual, reducing the risk of misclassification.  Even though only 
one carotid artery was screened in our study, a significant association between serum 
concentration of OPG and plaque area was demonstrated.  Many misclassified subjects with a 
low plaque burden in the screened carotid artery and with a high plaque burden in unscreened 
arteries arteries would attenuate this association.  
 
Validity 
In an epidemiological study the internal validity refers to whether the results are 
representative (true) for the population under study [158]. Generally, the internal validity may 
be threatened by selection bias, information bias and confounding.  In the Tromsø Study 
participants were selected by age. Selection bias may be caused by non-attendance. 
Participants in the study on plaque formation and growth (paper 3) were examined both in 
Tromsø IV and V.  The subjects with follow-up measurements were younger than those lost 
to follow-up. Moreover, they smoked less, fewer were teetotallers, and they were more 
physically active and had a lower prevalence of cardiovascular diseases. We believe that it is 
unlikely that this should invalidate our findings with respect to de novo plaque formation 
since only subjects without plaques at baseline were included. Whether the findings with 
regard to OPG and plaque growth would change if persons with more comorbidity were 
included cannot be definitively ruled out. However, we believe that the internal validity is 
good due to the high attendance rate.  Information bias might influence the quality of data 
such as smoking habits and self reported diseases.  Because diabetes mellitus was self 
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reported in the Tromsø study, we included HbA1c >6.1% in the definition of diabetes in 
papers 2-4. 
 
External validity is the degree to which the findings are generalizable to other populations 
[158].  This can be evaluated by comparing findings between similar studies in different 
populations and by applying the same models or analyses on other datasets.  Due to high net 
immigration from other parts of  Norway, the Tromsø population is relatively young [159].  
With regard to the incidence of cardiovascular disease, lifestyle, education, social factors and 
mortality, the population of  Tromsø is similar to other inhabitants in Norway [159]. 
 
Confounding and effect modification (interaction) 
A confounding factor predicts a disease or outcome, differs between the groups studied and is 
associated with the exposure under study. The factor’s association with disease arises from a 
causal pathway other than the one under study.  A confounding factor must not be affected by 
the exposure or the disease [158].  Confounding factors may lead to an underestimation or 
overestimation of the effect of an explanatory variable.  Confounding factors may be 
controlled for by matching in designing of the study or by stratification, or by the use of 
multivariable statistical methods in analyses of the data [156].  In  randomised controlled 
trials confounding tend to be small in large trials, but might be large in small randomized 
trials, despite that all potential confounders are expected to be evenly distributed between the 
groups being compared [160].  However, this is only on average across repetitions of  the 
randomization [158].  In our studies, we have adjusted for known risk factors by the use of 
multivariable statistical methods. In paper 3, associations between risk factors and change in 
plaque area was studied. It has been shown that adjustments for baseline values in some 
situations may induce an overestimation of the relationship between the predictor and changes 
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over time [161]. Therefore, we presented the changes of the plaque-area in subjects with pre-
existing plaques both with and without adjustments for the area at baseline. The relationships 
did not change significantly. When doing a large number of statistical tests in a data set there 
is always a chance for detection of false positive associations (type I error).  One solution is to 
be more stringent with “significance” levels, moving to p<0.001, rather than p< 0.05 [162]. If 
the test hypothesis is false but is not rejected, the incorrect decision not to reject is called a 
type II error [163].  The risk of type II errors increase with the number of variables included 
in the regression models, as degrees of freedom and thus power decrease. Interaction is 
present when the effect of a risk factor on an outcome is changed by the value of a third 
variable [164], as in paper 2 where the relation between OPG and CIMT changed across age 
groups. This is best dealt with by stratifying the sample.  Because the value of the third 




Subjects with missing values for a covariate in the regression models used (linear regression, 
logistic regression and proportional hazard model) were not included in the statistical analyses 
in our studies (complete-subject analysis).  It is a valid approach when the missing data are 
missing completely at random [165].  A drawback is that much recorded data will be 
discarded.  Imputation methods predict and fill in the missing values based on the observed 
data and the missing-data pattern [165].  A simple method of imputation is to replace missing 
values with the average value for that variable.  This method is likely to reduce the standard 
deviation (and standard error). In a large sample, few missing values will not be a serious 
problem. However, if there are many missing values it is potentially dangerous because 
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smaller standard errors are more likely to lead to significant results that are a product of the 
data replacement rather than a genuine effect [166]. 
 
Causality 
To assess causality sir Austin Bradford Hill proposed criteria which was an expansion of rules 
given by John Stuart Mill (1862) and Hume (1739) (reviewed by Rothman et al [167]).  The 
strength of the statistical associations (relative risk or odds ratio) has been considered 
important. The stronger the association, the more likely is a causal relationship. However, 
Rothman et al  points out that strong associations are neither necessary nor sufficient for 
causality, and weakness is neither necessary nor sufficient for absence of causality [167]. 
Consistency refers to repeated observations of an association in different populations under 
different circumstances. But as pointed out by Rothman et al [167], lack of consistency does 
not rule out causality because some effects are produced by their causes only under certain 
circumstances. Furthermore, a conclusion about inconsistency may be falsely drawn due to 
different power in the studies compared. Temporality means that a cause must precede the 
effect in time. As the dose of exposure increases, the risk of disease also increase (biological 
gradient). Plausibility refers to the scientific plausibility of an association and coherence with 
the current biologic knowledge. Experimental evidence can refer to laboratory experiments in 
animals, clinical trails or both. The last point proposed by Hill was analogy.  According to 
Rothman et al [167] “the insight derived from analogy is handicapped by the inventive 
imagination of scientists who can find analogies everywhere”.  A set of sufficient criteria for 
causality does not exist and observational studies cannot definitively examine whether 





5.2 Discussion of main results  
OPG, RANKL, and the cytokine network they are part of, have been proposed to represent the 
link between the skeletal system and the cardiovascular system because of the frequent 
coexistence of osteoporosis and cardiovascular disease [47].  In OPG
-/-
 mice severe 
osteoporosis developed leading to pathological fractures and in two thirds of the animals 
calcification of the subintima occurred in aorta and renal arteries [62]. These changes could be 
prevented by transgenic delivery of OPG during gestation.  The osteoporosis could be 
prevented by giving the animals OPG after delivery, however, the vascular calcification could 
not be reversed [111]. In rats vascular calcification induced by warfarin and vitamin D could 
to a large extent be prevented by injection of OPG in doses preventing bone loss [168].   
 
Increasing clinical evidence indicates that OPG, RANKL and the cytokine network they are 
part of, play an important role in cardiovascular disease. Clinically stable symptomatic 
coronary heart disease (CHD), acute CHD, CHD complicated with heart failure and 
symptomatic carotid atherosclerosis are associated with increased serum level and/or 
expression of OPG [110, 127, 169-171].  Serum levels of OPG have also been shown to 
predict atherosclerotic plaque growth [172], incident cardiovascular disease, and 
cardiovascular mortality in prospective studies in the general population and among 
postmenopausal women [151, 172-174].   
 
5.2.1 OPG and cardiovascular risk factors 
In the Tromsø cohort we found that serum OPG was significantly associated with several 
cardiovascular risk factors such as age, BMI (inverse),  systolic blood pressure, total 
cholesterol, HDL cholesterol, HbA1c, hs-CRP (men only), smoking (women only) and 
fibrinogen after adjustment for age.  However, no significant association was found between 
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OPG and triglycerides. In another study in men (n=522) with suspected coronary artery 
disease, OPG was positively correlated with serum homocysteine and negatively correlated 
with triglyceride serum concentrations.  OPG was not significantly  correlated with body mass 
index, creatinine, total cholesterol, HDL cholesterol, LDL cholesterol,  Apo A1 and Apo B or 
lipoprotein (a) [170].  In 201 patients with stable chest pain no significant correlation between 
OPG and BMI was reported and no difference was found in serum OPG levels when 
stratifying the patients by sex, hypertension, diabetes, hyperlipidemia and current smoking 
[169]. In a large population based multiethnic study (Dallas Heart Study, n=3386) age, female 
sex, smoking, hypertension, hypercholesterolemia, CRP, BMI, and diabetes mellitus were 
independently associated with OPG, whereas no significant correlation between OPG and  
HDL- and  LDL cholesterol was reported [175].  Thus, the relation between OPG and 
cardiovascular risk factors vary between different studies, and of the traditional 
cardiovascular risk factors some, but not all are associated with OPG. The interpretation of 
these findings are unclear, however it might be speculated that if a causal relation between 
OPG and CVD exists, it might be along a different causal chain than some of the traditional 
cardiovascular risk factors.   
 
5.2.2 OPG and surrogate markers for early atherosclerosis 
It is unclear whether OPG is a marker or mediator for atherosclerosis. Thus, it is relevant to 
study the relation between OPG and initiation of atherosclerosis.  Several studies have 
demonstrated that increased CIMT  is related to cardiovascular risk factor levels [176-179], 
prevalent cardiovascular disease [180], and atherosclerosis in other parts of the arterial system 
[181], indicating that CIMT may be regarded as a valid marker of generalized atherosclerosis. 




In our cross sectional study (n=6516) (paper 2) from a general population, a significant 
interaction between age and OPG was found. Increasing OPG concentrations reduced the risk 
of being in the top quartile of CIMT in subjects < 45 years, whereas subjects ≥ 55 years of age 
had increased risk of being in the top quartile. These age-dependant relations were present in  
crude- and adjusted models.  
 
Other surrogate markers for early vascular disease are flow-mediated dilatation (FMD) and 
artery stiffness. Endothelial dysfunction assessed by brachial artery FMD has been associated 
with cardiovascular events.  In a population-based cohort of healthy individuals a single 
nucleotide polymorphism in the promoter region of the OPG gene was positively associated 
with IMT and negatively with post-ischemic forearm blood flow [182]. In patients with 
peripheral artery disease, a negative association between serum OPG level and FMD was 
reported [183].  However, in multivariate models only metabolic syndrome was associated 
with FMD [183].  In 70 postmenopausal women with osteoporosis, but without coronary 
artery disease, serum level of OPG was an independent predictor of artery stiffness measured 
by pulse wave velocity and augmentation index [184].  
 
The main strengths of our study were the large number of participants and the wide age span.  
When the dependent variable (CIMT) is measured on a continuous scale, the power to 
quantify the effect of risk factors, as well as interaction among risk factors, is increased 
compared with studies in which the end point is defined only by the presence or absence of 
clinical disease or plaques. Due to low prevalence of atherosclerotic plaques in young 
subjects, surrogate markers for early atherosclerosis are probably the only feasible method for 
detecting an interaction between OPG and age in a model studying atherosclerosis as 




Two small studies on postmenopausal women and women with previous gestational diabetes 
found significant positive associations between serum OPG and CIMT [115, 185]. In the 
Bruneck study (n=915) the positive association between OPG and CIMT in crude analysis fell 
short of statistical significance in multivariable analyses [172].   The age range was 40-80 
years [172], diminishing the possibility to detect an interaction between age and OPG. In our 
study plaque thickness was included in the measurement of CIMT, whereas in the Bruneck 
study CIMT was quantified at the far wall
 
of plaque-free sections of the common carotid 
arteries [172].  This might partly explain why no association was detected in the Bruneck 
study after adjustment, whereas in our study the positive association between OPG and CIMT 
in older subjects to some extent reflects the association between OPG and atherosclerotic 
plaques. However, after exclusion of subjects with plaques in our study, an independent 
positive association remained in subjects aged ≥ 55 years, indicating that other factors 
probably are of importance.  The switch in the association across age groups was unique for 
OPG in the multivariable model included traditional cardiovascular risk factors.  Howard and 
co-workers studied the relation between cardiovascular risk factors and subclinical 
atherosclerosis assessed by ultrasound across age groups [179].  They reported that risk 
factors associated with atherosclerosis increased across all ages; however, all subjects were 
older than 45 years [179]. The age-dependent switch in the relation between serum OPG and 
CIMT also attracts attention to the possible influence of sex hormones and menopausal status.  
Unfortunately, we do not have accurate information of the menopausal status or serum levels 
of sex hormones in our cohort.  It is unlikely that the menopausal status and serum levels of 
sex hormones are unrecognized confounders, since the risk estimates are similar in men and 
women across all age-strata, assuming that women below 45 years are premenopausal and 
above 55 years are postmenopausal.     
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Although no firm conclusions can be drawn from a cross sectional study where unrecognized 
confounders could not be ruled out, it is tempting to suggest that the inverse relation between 
OPG and CIMT in young age represent a counter regulatory mechanism in order to keep 
excessive activation of inflammation pathways and other injurious stimuli under control in 
atherogenesis. Our unexpected finding provide further evidence to the concept that OPG do 
not promote early atherosclerosis or even inhibits development of atherosclerosis. 
 
5.2.3 OPG and plaque formation and growth.  
Consistent with the finding in the Bruneck study [172], we found in our cohort of 4520 
subjects (paper 3) followed for up to 7 years,  no association between OPG and de novo 
plaque formation [186].  In subjects with plaques at baseline, a significant association 
between OPG and growth of plaques was detected in women (n=928), but not in men 
(n=1100) in our study.  Furthermore, we found no significant relations between sRANKL and 
plaque formation and growth [186].  In the Bruneck study, a significant association between 
OPG and plaque growth was assessed in 326 subjects with plaques at baseline [172]. In 
contrast to our study, sex-specific data was not presented [172].   
 
The method for plaque assessment was different between our study and the Bruneck study.  In 
the Bruneck study plaque thickness was measured, and in our study plaque area was 
calculated.  Others have shown that assessment of change in plaque area was superior to 
change in plaque thickness in detecting changes in plaque burden during 2 years [187]. 
Whether this is true for longer observation times is uncertain.    
 
Although both the Bruneck study and the Tromsø study are from the general population, a 
possible difference between the populations was that in the Bruneck study more than 50% of 
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subjects in tertile 3 of OPG were considered to suffer from a chronic infection [172].   The 
high number of participants with plaques at baseline in our study reduces the risk of observed 
associations being the result of statistical errors. The lack of consistency between men and 
women with regard to the relation between OPG and plaque growth questions the role of 
serum OPG in growth of plaques. Experimental studies in mice indicate that OPG is not 
involved in initiation and growth of plaques [114, 188, 189].   
 
5.2.4 OPG and plaque echogenicity 
Previously, data from the Tromsø Study has shown an association between  low bone mineral 
density and presence of echogenic carotid plaques [54]. In our case-control study (paper 1), 
serum OPG was lower in subjects with echogenic plaques compared to subjects with 
echolucent plaques. No difference in OPG was found between controls and subjects with 
echolucent plaques. In subjects with plaques, OPG levels decreased linearly with increasing 
echogenicity assessed by GSM [190].  Plaques that appear echolucent are lipid-rich, whereas 
echogenic plaques have higher content of dense fibrous tissue and calcification [191].  
No significant differences between the groups in our study with regard to cerebrovascular risk 
factors, included prior cardiovascular disease, strengthen the results despite the low number of 
participants.  Interestingly, the difference between OPG serum levels in subjects with 
echogenic plaques and controls increased after exclusion of subjects with prior cardiovascular 
disease.  To the best of our knowledge, this was the first study to show an association between 
serum OPG and plaque morphology in humans.   
 
Most studies have shown increased serum OPG in subjects with atherosclerosis and in 
subjects with heart failure, probably due to continuous inflammatory stimulation. However, in 
a case-control study in young survivors of uncomplicated myocardial infarction (no heart 
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failure or relapse of angina/myocardial infarction) serum OPG was equal to age and sex 
matched controls 1 to 4 years after the infarction [116].  A possible explanation might be that 
the acute inflammatory response had subsided years after the acute event.   In the present 
study (paper 1), the participants were recruited from a population study and included on the 
basis of their plaque status and not clinical disease.  This may partly explain that there was no 
difference in OPG serum level between controls and subjects with echolucent plaques, and 
even significantly lower OPG levels in subjects with echogenic plaques.  These findings 
support the notion that the increased serum level of OPG observed in clinical disease could be 
a result of chronic inflammation.  
 
Animal studies indicate that OPG influences vascular calcification and plaque morphology.   
Both osteoporosis and subintimal vascular calcification ocurred in OPG
-/-
 mice [62], and 
vascular calcification induced by warfarin treatment or high doses of vitamin D was reduced 
in rats treated with OPG [168]. Increased vascular calcification and plaque size appeared in 








  mice, indicating 
that OPG acted as an inhibitor of vascular calcification and of plaque growth [114]. In Apo  
E
-/-
 mice with intact endogenous OPG production, treatment with OPG did not influence 
atherosclerotic lesion size, but promoted smooth muscle cell accumulation, collagen fiber 
formation and development of fibrous caps in the atherosclerotic plaques [188].  OPG 
treatment did not affect markers of inflammation [188].   Serum OPG increased within few 
weeks in ldlr
-/-
 mice fed a diet promoting atherosclerosis [189].  Administration of 
recombinant OPG did not influence atherosclerotic plaque size, but reduced vascular 
calcification [189].  Thus, lack of OPG seems to promote vascular calcification, whereas 
treatment with OPG promoted fibrous cap formation and reduced calcification in animals with 
intact endogenous OPG production.  Less expression of OPG has been demonstrated in aortic 
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stenosis with calcified valves in humans than in normal controls [192].  RANKL was not 
expressed in controls, but in calcified valves [192] indicating that the OPG/RANKL system 
seems to be involved in the regulation of calcification also in the human vascular system.  
 
Recently, a strong negative association between serum OPG and GSM (r=-0.575, p<0.001) 
was reported in subjects with prior cerebrovascular disease [193]. 3-Hydroxy-3-
methylglutaryl-coenzyme A reductase inhibitors (statins) are used to prevent atherosclerotic 
vascular events and death through lowering of LDL cholesterol levels [194, 195]. Statins 
seem to be able to prevent ischemic coronary artery disease (CAD), heart failure and left 
ventricular dysfunction [196, 197]. Therefore, it has been hypothesized that statins have 
favorable pleiotropic effects including improvement of endothelial function and reduction of 
inflammation beyond their cholesterol-reducing effects [196, 197].   In humans, use of statins 
has been reported to be associated with increased bone mineral density [198]. Atorvastatin 
increased OPG mRNA levels and protein secretion three fold in human osteoblasts, 
expression of differentiation markers, alkaline phosphatase and osteocalcin increased, and the 
inhibitory effect of glucocorticoids on OPG production was abrogated [199].  This may 
contribute to the beneficial effects of statins on the skeleton [199].  In human endothelial cells 
and SMCs, atorvastatin reduced TNF-alpha induced OPG expression [93].  In subjects with 
hypercholesterolemia and type 2 diabetes, treatment with low doses of pravastatin (5-10 
mg/per day) increased serum OPG significantly (6-7%) after 3 months and it remained 
elevated after six months [200].  In two other studies in type 2 diabetic patients with 
microalbuminuria and nephropathy, respectively, simvastatin treatment reduced OPG whereas 
lovastatin treatment increased OPG serum level [201, 202].  In a double blinded study in 27 
patients with stable CAD patients received either simvastatin 40 mg/d or fenofibrate 160 
mg/d.  The OPG serum concentration increased significantly after one month of treatment in 
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both groups, by 26.8% and 33.3%, respectively, and the effect remained stable after additional 
two months of treatment [203].  In subjects (n=140) with moderate carotid stenosis 
atorvastatin reduced serum hsCRP and OPG levels from baseline to follow-up at 1 year.  
Aggressive lipid lowering therapy reduced the concentrations more than moderate doses of 
atorvastatin.  The GSM score increased, reflecting increased plaque echogenicity [204].   
 
Thus, the effects of statins on serum OPG diverge in different populations and between 
statins.  Whether the effect of statins on plaque echogenicity is mediated by the OPG/RANKL 
axis and/or other mediators is not known. However, the consistent inverse relation between 
OPG and echogenicity in subjects with prior cerebrovascular disease [193], in the intervention 
study [204] and in our study strengthen the notion that OPG and plaque echogenicity are 
related also in humans as demonstrated in experimental animal studies.    
 
5.2.5 OPG and future cardiovascular disease and mortality 
Limited data are available on the impact of OPG to predict risk of incident myocardial 
infarction, stroke and mortality in the general population.  In our study (paper 4) OPG 
predicted risk of myocardial infarction and ischemic stroke.  In tertile 3 versus tertile 1 of 
OPG the relative risk of myocardial infarction and ischemic stroke increased 1.4 fold and 2.0 
fold, respectively, demonstrating a dose response relationship. In the Bruneck study OPG was 
reported to be associated with incident cardiovascular disease (CVD) and cardiovascular 
mortality, respectively [172].  However, CVD (number of events=128) was a composite of 
transient ischemic attacks, ischemic stroke, myocardial infarction, peripheral artery disease, 
revascularization procedures, and vascular deaths (number of deaths=56).   Thus, vascular 
deaths represented more than 40% of incident cardiovascular disease, and a significant 
association between OPG and vascular deaths alone was reported [172].  In the same 
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population, no association was reported between serum level of sRANKL and carotid- and 
femoral atherosclerosis, whereas a significant association between  sRANKL and 
cardiovascular events  was found [152]. 
 
In a nested prospective case-control study (within the EPIC-Norfolk study) 951 apparently 
healthy individuals, who developed a coronary event during 6 years of follow-up, were 
matched by age and sex by 1705 healthy controls. Baseline serum OPG was associated with 
future coronary events, in contrast to  baseline sRANKL concentration [173].  In the 
Offspring cohort of the Framingham Heart Study (n=3250), OPG serum levels, but not 
sRANKL, were associated with cardiovascular disease (fatal and non-fatal myocardial 
infarction, coronary insufficiency, heart failure and stroke) and all-cause mortality during a 
mean follow-up of 4.6 years [205]. The association with CVD failed to reach statistical 
significance when OPG was categorized in quartiles [151].  In 897 patients with acute 
coronary syndrome followed for median 89 months, baseline OPG serum concentration was 
significantly associated with mortality and hospitalization for heart failure, but not for stroke 
and recurrent myocardial infarction after adjustment for other risk factors [206].  In patients 
with suspected stable angina pectoris undergoing elective coronary angiography (n=1025), 
strong associations between OPG concentrations and all-cause mortaility, CVD mortality and 
incidence of myocardial infarction in univariable analyses were reported [207].  However, 
after adjustment for cardiovascular risk factors no significant associations were reported, 





In patients with large vessel disease stroke, OPG were significantly higher compared to 
patients with small vessel disease and controls [208].  In a case-control study in 
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postmenopausal women (n=490), OPG was measured at baseline and subjects were followed 
for 12 years [124].  241 incident strokes occurred whereas 247 controls were randomly 
selected from the cohort. Associations between serum OPG and risk of fatal ischemic stroke, 
cardiovascular mortality and all-cause mortality, but not with nonfatal ischemic strokes were 
reported [124].  In our prospective cohort study (paper 4) OPG showed a significant 
interaction with sex for ischemic stroke as endpoint, the risk estimate for women was higher 
than in men. The discordance between the case-control study in postmenopausal women and 
our study might be explained by different study populations and study design.  In a nested 
case-control study (median length of follow-up 3.1 years) within a large unselected cohort 
from the general population, 254 cases with verified incident acute ischemic stroke and 254 
age- and sex-matched controls were studied [209]. The adjusted odds ratio for ischemic stroke 
was 0.87 (95% CI 0.46-1.63) comparing participants in the highest quartile of OPG 
concentrations with those in the lowest quartile. The authors suggested that this could indicate 
a different pathogenic process in stroke development from that in ischemic heart disease, 
where OPG has been shown to be a significant predictor. The result of our study does not 
support this notion.  
 
In our study significant associations between OPG and total mortality and death of 
myocardial infarction and ischemic stroke were detected, respectively. We also found a 
significant association between OPG and death of non-vascular causes.  To our knowledge, 
this has not been previously reported.  In the Bruneck study, subjects with cardiovascular 
disease prior to baseline was included in most analyses, and no association between OPG and 
death of non-vascular causes (number of events=100) was found [172].  However, after 
exclusion of subjects in the Bruneck study who had experienced cardiovascular disease before 
study baseline (n=65) the risk (hazard ratio (95% confidence interval)) of death after 
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adjustment for other risk factors was in OPG tertile 2; 1.1 (0.6-2.1) and in tertile 3; 1.6 (0.9-
2.9) versus tertile 1 [172].  In our study the risk of death in tertile 2 was 1.2 (0.9-1.5) and in 
tertile 3 1.6 (1.3-2.1) versus tertile 1. Thus, the risk estimates are practically identical in the 
two population based studies. The difference in statistical significance between the two 
studies is most likely due to differences in statistical power.   
 
5.2.6 OPG/RANKL/RANK - marker or causal factor for cardiovascular disease?                                                     
The relation between OPG and vascular disease could be a causal relationship. Alternatively, 
OPG might be a marker of atherosclerosis or OPG and atherosclerosis could share a common 
etiologic factor.  Whether studies in cell cultures reflect the in vivo situation and to what 
degree the results of studies in animals are transferable to humans, are uncertain.  Browner et 
al [124] hypothesized that increased
 
serum OPG levels in humans could be a response to, 
rather than a cause
 
of atherosclerosis or vascular calcification, perhaps in an attempt
 
to 
regulate those processes. Another explanation could be that the higher OPG levels are a result 
of decreased clearance of OPG, perhaps because
 
of increased binding of RANKL [124]. 
An inherent limitation using serum concentration to study the relation to disease is to what 
extent serum concentrations reflect what is going on within the tissues. Different effects of the 
OPG/RANKL system on the various stages of atherosclerosis such as plaque formation, 
plaque modelling and calcification are plausible.   
 
Our epidemiological studies suggest that OPG is not a main player in atherosclerotic plaque 
formation or growth of plaques (paper 3). However, we found that serum OPG predicted 
myocardial infarction and ischemic stroke during 12 years of follow up (paper 4) independent 
of traditional risk factors.  With each SD higher level of OPG the future risk of cardiovascular 
diseases and mortality increased 20-44% after multivariable adjustment. In comparison, the 
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risk of myocardial infarction in our study with each SD higher level of total cholesterol was 
30% (unpublished data).  In a recently published meta-analysis the increased risk of coronary 
heart disease with each SD higher levels of log CRP  was 44 % after adjustment for 
conventional risk factors and 23% after inclusion of fibrinogen in the multivariable model 
[210].  In a large population based study in apparently healthy women followed for a mean of 
eight years the relative risk of first cardiovascular events according to quintiles of LDL 
cholesterol compared to the lowest quintile was 0.9, 1.1, 1.3 and 1.5, respectively [211].  The 
relative risk in our population for first myocardial infarction was in comparison 1.0, 1.1, 1.1 
and 1.5 compared to the lowest quintile of OPG. A causal relationship between OPG and 
cardiovascular disease is supported by the clear temporal sequence. Furthermore, serum OPG 
at baseline discriminated between thrombotic and hemorrhagic stroke, possibly indicating that 
OPG is not merely an unspecific marker for poor health and chronic inflammation.  However, 
the number of hemorrhagic events was low so interpretation should be done with caution.  
The strength of associations found for established causal risk factors and for OPG cannot be 
used to conclude that there is a causal relationship or that a causal relationship does not exist. 
Although several studies have shown an association between OPG and cardiovascular disease 
and mortality, mechanisms are uncertain.   
 
Homocysteine is another biomarker where extensive epidemiological data support that 
homocysteine might be a causal risk factor for cardiovascular disease (reviewed in [212]). In a 
nested case-control study in the Tromsø population a 4 µmol/L (1SD 4.7 µmol/L and 3.7 
µmol/L in cases and controls, respectively) increment in serum homocysteine was associated 
with 32%  increased risk of coronary heart disease after adjustment [213].  However, 
intervention trials with B-vitamins lowering plasma homocysteine have not shown a clear 




Treatment with recombinant OPG or the monoclonal antibody denosumab to RANKL, have 
shown beneficial effects in the skeletal system.  Large trials, such as the denosumab trial for 
the prevention of fractures in postmenopausal women, might also as a “side effect” contribute 
to increased knowledge about the relation between the OPG/RANKL system and the 
cardiovascular system.   
 
Since the OPG/RANKL system most likely is not causally related to plaque formation and 
growth, an alternative role in the pathogenesis of cardiovascular disease should be searched 
for.  Besides an effect on plaque modeling and stability, it might be speculated that the 
OPG/RANKL system could be involved in thrombosis (see section 1.7).   
 
The utility of serum markers as risk predictors may not depend on their pathogenic 
importance, but rather on their ability to reflect important pathogenic processes [173].  An 
experimental study in mice suggested that RANKL, rather than RANKL inhibiton was 
responsible for exacerbation of vascular disease. Human RANKL
 
knock-in mice had 
implanted prednisolone pellets to induce osteoporosis. These mice were responsive to 
denosumab in contrast to wild type mice [218]. Treatment
 
with denosumab reduced aortic 
calcium deposition of prednisolone-treated
 
huRANKL-knock-in mice by up to 50%.  TRAIL 
might also be of importance for atherosclerosis. An experimental study in apo E-/- mice with 
diabetes mellitus showed that recombinant human TRAIL significantly attenuated the 
development of atherosclerotic plaques, induced apoptosis of infiltrating macrophages and 
increased the vascular smooth muscle cell content, suggesting that OPG could contribute to 
cardiovascular risk by inhibiting a possible anti-atherosclerotic activity of circulating TRAIL 
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[219].   Reduced level of soluble TRAIL in patients with acute myocardial infarction and 








In the case control study (paper 1) OPG and carotid plaque echogenicity measured by GSM 
showed an inverse relationship, i.e. the OPG serum level was significantly lower in subjects 
with more echogenic (fibrotic and calcified) plaques than in subjects with echolucent (lipid 
rich) plaques and controls. This finding is consistent with animal studies where lack of OPG 
was associated with calcification and treatment with OPG decreased calcification.   
 
In our cross sectional population based study (paper 2) we found that the relation between 
serum OPG and carotid intima media thickness (CIMT) changed across age groups. In young 
subjects (25- <45 years), higher OPG levels reduced the risk of being in the uppermost 
quartile of CIMT, whereas subjects ≥ 55 years of age showed a reversed association. Of all 
the established risk factors for cardiovascular disease included in the multivariable model, the 
switch in the association across age groups was unique for OPG.  
 
In the population based prospective study (paper 3), no association was found between serum 
level of OPG at baseline and de novo carotid plaque formation during seven years of follow 
up.  A significant association between OPG and plaque growth was demonstrated in women, 
but not in men. This inconsistency challenges the concept that OPG is related to plaque 
growth.  Together, paper 2 and 3 suggest that OPG is not involved in the initiation of 
atherosclerosis. The negative association between OPG and CIMT (paper 2) may indicate that 
increased serum OPG could be favourable in younger subjects.   
Serum OPG at baseline was independently associated with incident myocardial infarction and 
ischemic stroke, but not hemorrhagic stroke during 12 years of follow-up (paper 4).  OPG 
predicted total mortality, deaths of myocardial infarction and ischemic stroke, respectively.  
Furthermore, an association between OPG and death of non-vascular causes was detected.  
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These findings may indicate that OPG is a mediator in cardiovascular disease and may also 





Further implications  
Our studies do not support a role for OPG in initiation of atherosclerosis and question the role 
of OPG in plaque growth.  OPG predicts myocardial infarction and ischemic stroke, diseases 
that most often are caused by plaque rupture with subsequent thromboembolic complications.  
OPG has been reported to bind to trombospondin-1 and vWF.  A possible role for OPG in the 
regulation of thrombus formation has been proposed. Thus, both basal mechanistic studies 
and population based studies on the relation between OPG and venous thrombosis are needed.  
Intervention trials are important for gaining more knowledge about the relation between risk 
factors and disease.  Intervention trials focusing on reducing OPG in humans will probably 
not be performed due to the pleiotropic effects of OPG and risk of serious side effects.     
 
OPG, RANKL and possible effects of medication  
The TRAIL/OPG/RANKL system affects the cardiovascular system, the immune system and 
apoptosis.  OPG seems to  downregulate  the immune response by decreasing dentritic cell 
survival [70].  In vitro studies indicate that OPG may act as a survival factor for tumour cells 
from both solid tumours [74, 78] and haematological malignancies [79].  Denosumab is a 
human monoclonal antibody with a high affinity
 
and specificity for RANKL, and thereby 
inhibits
 
the differentiation, activity, and survival of osteoclasts.  A clinical trial in women with 
osteoporosis showed a reduction in the risk of vertebral, nonvertebral, and hip fractures [90]. 
Although denosumab is specific for RANKL and does not block TRAIL, it might be 
speculated that possibly shifting the balance between the cytokines in the 
TRAIL/OPG/RANKL system could lead to side effects that could be harmful or beneficial.   
If the effect of OPG/RANKL system on the cardiovascular system is harmful and that effect 
is mainly mediated by RANKL, prevention of binding of RANKL to RANK could be 
associated with a beneficial effect.  If binding of denosumab to RANKL leads to enhanced 
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activity of OPG, it might be speculated that increased risk of infection or cancer could occur. 
During 36 months of treatment  with denosumab in postmenopausal women (n=7868), no 
significant increase in the risks of cancer, infection or  cardiovascular disease were observed 
[90].  The overall incidence of new malignancies was 4.3% in the placebo and 4.8% in the 
denosumab groups. According to Amgen’s home page there were no significant impact of 
denosumab on new malignancies in the breast (0.7% placebo vs. 0.9% denosumab), 
reproductive (0.2% placebo vs. 0.5% denosumab), and gastrointestinal systems (0.6% placebo 
vs. 0.9% denosumab) [221]. In men with prostate cancer treated with denosumab every 6 
months for three years, no increase in new primary cancers occurred in the treatment group 
compared with the placebo group [222].  In the Bruneck study, no significant associations 
were reported between sRANKL, OPG and the incidence of cancer (n=146) and deaths from 
cancer (n=81) [223]. 
 
The observed association between OPG and non-vascular mortality in our study (paper 4) 
needs further exploration.  The relation between OPG and cancer needs to be addressed in 
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PROCEDURES FOR MEASUREMENTS OF INTIMA-MEDIA THICKNESS AND 
RECORDING AND MEASUREMENTS OF PLAQUE OF THE RIGHT CAROTID 







1. The Acuson ultrasound instrument is switched on. 
 
2. A videocassette is inserted in the videorecorder. 
 
3. Check that the videotape has been wound to the right position, do not overwrite previous 
recordings.  
 
4. Cassettes are marked with serial numbers, uneven numbers for Acuson I, even numbers 
for Acuson II. 
 
5. The initials and the identity numbers of the participant and the sonographer number 
(Jon=1, Eva=2, Oddmund=3) are written on each ultrasound image recorded. Labels with 
the ID-number of the participants are attached to the registration form, in which all 
ultrasound data obtained from the participants are filled (plaque localization, size, number 
per artery, "missing measures" codings, etc). 
 
6. A RES-field, appropriately adjusted to a maximum width of the screen and a depth of a 
little more than 2 cm of the B-mode image, is positioned on the screen for obtaining 
images from the carotid artery of optimal quality. 
 
7. The subject is examined in a supine position with the head slightly rotated to the left. 
ECG-pads are attached to both arms and the right leg (or abdomen) (lead I), and the right 






8. The examination starts with identification of crossectional B-mode images of the carotid 
artery, and, if necessary for identifying purposes, in combination with colour-Doppler 
and/or pulsed wave Doppler 5 MHz. The examination starts caudally in the neck, 
normally just above the clavicle, then moving the probe upstream with simultaneous 
rotation movements to search for plaques also at the circumference of the vessel. Thus, the 
carotid artery is searched from the proximal part of the common carotid artery (CCA), 
upstream to the bifurcation (BIF), and as far up in the internal carotid artery (ICA) as 
technically possible. A plaque is defined as a presumed atherosclerotic lesion of the intima 
layer of the vessel wall presenting as a focal protrusion of more than 50% of the intima-
media thickness (IMT) of the surrounding vessel wall, often with deviating echogenicity 
compared to other part of the wall of the artery. Whether a plaque is present or not is a 
decision taken by the sonographer during the examination. Live, crossectional imaging of 
the whole carotid artery is recorded on the videotape. 
 
9. A ultrasound examination sequence is then performed in the triplex modus (i.e., 
combination of pulsed wave Doppler, colour Doppler, and B-mode examination) from just 
above the clavicle and as high upstream above BIF as possible. The objective of this part 
of the examination is to look for stenotic areas along the artery. However, if plaques later 
during the B-mode scanning procedures are found suspicious of a hemodynamic 
significant stenosis, a new triplex examination is performed to reevaluate the flow 
conditions. A live triplex sequence of the relevant part of the carotid artery is recorded on 
the videotape if a stenosis is suspected. 
 
10. B-mode longitudinal ultrasound scanning of the carotid artery is then performed. To get 
an optimal topographic reference, the examination is starting as proximally as possible in 
CCA. The probe is then moving upstream with simultaneous rotating movements to look 
for plaques in all segments, both in the near and the far wall. 
If a plaque is found, a frozen image of the vessel wall with the plaque 
presented as distinctly as possible and after guidelines according to elementary ultrasound 
principles such as vertical  propagation of the ultrasound beam, presentation of the plaque 
in the full diameter of the vessel and not in chord, not cutting the plaque skewly causing a 
falsely too large thickness of the plaque. To ensure the quality of plaque registration, some 
technical points may be of help: The plaque should be "attached" at its both ends to the 





double-lined structures should best be visible both in the near and the far wall at the same 
time. When the echogenicity  obtained is as high as possible(as bright as possible), this is 
an indication that the ultrasound waves have cut the plaque optimally. 
The presentation of the plaque causing the largest thickness of the plaque is 
chosen for recording of a frozen image on the videotape. An electronic caliper is put on 
the top of the plaque (at the interface between the surface of the plaque and the vessel 
lumen) and another caliper in the presumed transition zone between the media and the 
adventitia layer. The distance between the calipers is the thickness of the plaque, and that 
value is put on the registration form in the appropriate box. The B-mode image of the 
plaque is identified correctly by marking on the display what has been found, and where: 
PLAQUE ICA FW (a plaque in the far wall of the internal carotid artery), PLAQUE 
BULB NW (a plaque in the near wall of the bifurcation), etc. A short recording of 
approximately 5 sec. is videotaped. If more than one plaque is present at a site (e.g., in the 
far wall of ICA), the largest is chosen and recorded. 
  After identifying and recording of plaques, imaging procedures to get optimal 
measures of IMT from CCA and BIF are performed. Optimal images are available when 
distinct double contours of the vessel wall typical for the intima-media complex can be 
seen. It is important that the longitudinal axis of the insonated vessel wall is perpendicular 
to the ultrasound beam direction. To avoid falsely too thick intima-media layer, the IMT 
should be measured in the full diameter of the artery and not in a chord. When satisfactory 
images are achieved, R-wave triggered IMT-registrations are recorded on a cineloop 
containing more than 20 images. Afterwards, the images stored in the cineloop are 
scrutinized and 3 of most representative images, and each at least 10 images apart, are 
selected for recording on the videotape. 
  Regarding IMT measurements in the BIF, the start of the BIF is first identified 
and then marked with an arrow. This is the point where the parallell walls of CCA are 
starting to diverge. If the probe throughout the recording process in the cineloop has 
changed position, the placeing of the arrow marker must be adjusted accordingly. It is 
important to underline that it is the sonographer who places the marker and not the off-line 
reader of the IMT measurements. The arrow-setting has to be as precise as possible, 
particularly when a plaque is located in the borderzone between BIF and CCA to avoid 
over- or underestimating of IMT. 
  The target site for IMT measurements of BIF is the 1 cm area from the start of 





may, however, be performed on this shorter distance if the live sequence shows that this 
part of the vessel wall is representative of the rest of the 1 cm area. This shorter, 
measurable distance is marked with an electronic star. The 3 chosen images are marked 
BULB1, BULB2, and BULB3 and recorded on the videotape. If no measurable image is 
possible to obtain, an image from BIF still is recorded and marked MB, i.e., "missing 
bulb". If only one or two images from the cineloop is considered measurable, these are 
recorded and MB for one ore two images also recorded. IMT measurements from the near 
wall IMT in BIF were not recorded. 
 
11. After examination of the BIF, B-mode scanning of CCA is performed, starting at the 
bifurcation and downstream as far as possible. Registration and measurements of plaque 
are done in the same way as mentioned above. The images with plaques are marked 
PLAQUE CCA FW and PLAQUE CCA NW, videorecording is performed of both the 
live sequence and of the frozen, marked images. Three optimal images for measuring IMT 
are chosen from the cineloop, from the arrow mark indicating the transition between BIF 
and CCA and 1 cm distally as described above. The images are marked CCA1, CCA2, 
and CCA3. Non-measurable images of IMT are also handled as described previously: an 
image of the CCA vessel wall is frozen and marked MC. All measurements on the far wall 
refer to the so-called "leading edge" principle (or "upper demarcation line" principle). 
These structures are not being different in thickness when the emitted power (mW/cm
2
) or 
of the ultrasound instrument's gainsetting are changed (nor are biologic different 
conditions of subjects examined). 
  Near wall measurements, however, are performed on "far edge" principles 
which means that IMT to some degree may be dependent on some of the technical 
conditions mentioned above (e.g., gainsetting). Standardized examination conditions 
therefore are particularly important for near wall measurements. It is, however, not 
possible, in technical terms, to obtain such ideal conditions because individually 
instrument adjusting alternatives always are more or less involved in processing optimal 
B-mode images. However, setting of functions such as emitted power of ultrasound, 
preprocession, postprocession, gainsetting, etc, should be standardized as much as 
possible. Biologic inter-individual differences (obesity, position of the neck arteries, short 
or long necks, etc.) causing need of some different adjustments, however, are not possible 
to standardize. If the visibility of IMT and plaques is not optimal, the gainsetting (both the 





The gain should all the time be set high enough to identify soft, echolucent plaques but not 
too high to conceal small plaques due to "ultrasound noise" Only as an exception, 






12. Do not remove the cassette from the videorecorder before end of the day, or when the 
cassette is full. 
 
13. Check that the registration form is completed appropriately. In the "Remarks" box, coding 
      for reasons for missing of measurable images should be done: 
  MB 1= missing images from BIF due to obesity 
  MB 2= missing images from BIF due to a steep angle between CCA and BIF 
MB 3= missing images from BIF due to technically difficult examinations 
            (e.g., short neck) 
MB 4= missing images from BIF due to previous surgery or radiation 
MB 5=other reasons 
      In the same way, missing coding for CCA and ICA is performed: MC 1, MC 2, etc. 
 
14. A referral form to Department of Neurology, University Hospital, Tromsø is completed 
when a suspected carotid stenosis or occlusion are found. Two criteria for defining a 
stenosis is used. Either a velocity increase across an atherosclerotic plaque in BIF of 0.1 
m/sec or more or 0.2 m/sec or more in ICA, compared to the reference velocity distally in 
ICA; or a plaque thickness that constitutes 35% or more of the lumen diameter at the 
plaque site. The velocities should be manually angle-corrected for the angle at which 
Doppler-beams are emitted into the vessel. Occlusion is suspected when the open lumen 
of the artery is not visible on B-mode or if there is a visible occluding plaque in the artery, 
and there is no detectable flow in the artery by pulsed Doppler or by colour-Doppler.  
The referral threshold should be low to avoid false negative stenosis cases. The person 
who is referred, should be given a written and verbal information of the findings and 
clinical implications before leaving the room. 
Protokoll for'oGrabbing"
Digitalisering av plakk opptak fra SVHS-kassett
PC + s1q.jerm, samt Panasonic 7560 + skjerm sl6es pi. Videoskjermen er ferdig
forh&ndsinnstilt pe PAL.
Videokassetten settes i. Spol fram til aktuelle plakk-opptak. Sjekk hele tiden mot
skjemaet over alle plakkopptak (Excel-ark) for 6 forsikre seg om at man ffir digitalisert
alle opptakene. Fin-innstill inntil framet man har pi videoskjerrnen er stillestiende,
uten'sng' .
Start programmet Matrox Intellicam fra PC'ens skrivebord.
Dersom det erforste 'grab'fra kassetten skal GSM for bakgrunnsfargen i opptaket
testes med folgende underprosedyre (1-5), ellers fortsett p6 neste punkt:
l. Grab et bilde (se under prosedyren for GRAB! under).
2. Save bildet under katalogen C:Wy documents\Plaque\Test som test.tif.
3. Last bildet inn i Adobe Photoshop 3.0.
4. Trykk pi Bilde4qodus - Qritoner, og deretter 
'OK' pf, minimenyen 'Ta
bort fargeinformasj onen?'
5. Med firkantpekeren, avgrens et 'svart' omr&de utenfor delen av skjermen
ved Doppler-bildet, og trykk Bllde - $istogram. Middelverdien skal vare
mellom l-3. Dersom den er <1 eller >3, stilles knappen 'BLACK LEVEL'
pi Panasonic 7650's 'TBC CONTROL' hhv litt med/mot klokka, og
prosedyren gjentas inntil middelverdien er mellom 1-3 (men ikke 0, da kan'BLACK LEVEL' vere stilt for lavt!). Dette gientas ved oppstart, og hver
gang man skifter kassett, for i sikre seg om at bakgrunns-svart er svart.
GRAB!
Trykk Ctrl + M, eller trykk pe kamera-ikonet under menylinja (nr 6 fra venstre) for 6
grabbe bildet.Dette kan gjores gjentatte ganger inntil man har et mest mulig rent bilde.
Fsrste gang man 'grabber' etter oppstart av Matrox Intellicam, ffir man opp
undermenyen 'Digitizer Configuration Format'- Velg 'pAL' i boksen og trykk 'oK'.
Lagre bildet ved fl trykke Alt+F - A, eller F'ile - save As, (,men ikkectrl+g, e11s1
Att+F - S, da lagres nemlig over sist lagret fil!) og skriv da inn filnavnet som er
oppgitt i skjemaet. OBS - dobbelsjekkfor evt. slcrivefeit. Filen lagres i katalogen som
samsvarer med tapenummeret, (Tape 01 osv...) under hhv Tr4 eller Tr5. (For i
forenkle rutinen med filnavn, kan navnet kopieres fra Excel, og limes inn i filnavn-
rubrikken i Intellicam, for deretter fl trykke <Enter> for 5 lagre...men clobbelsjekk for
skrivefeil likevel!!). Skriv inn 'grabe'- dato (format: ddmmee, for eksempel0l l102,
150103) i Excel-arket som en 'kvitterins'.
' Spol si flam til neste plakk-opptak, fin-innstill og gjenta prosedyren...l 1000 ganger!!
Einar Fosse 2002
t'Grabbing"-protocol
(Digitizing plaque images from SVHS-cassette)
PC + monitor, and Panasonic 7560 video recorder * monitor are switched on. The
video screen is preset o PAL.
The videocassette is inserted in the video recorder. Wind on to the plaque image of
interest. Check continuously the plaque registration form (Excel-sheet) o ensure that
no plaque images are missed. The frame on the video screen should be smoothly
adjusted until it is stationary, without any "snow".
o Start Matrox Intellicam on the PC desktop.
If this is they'rsl 'grab'from the videocassette, the GSM-value for the background
colour of the recorded image should be calibrated according to the following
procedure (1-5). Ifnot, proceed to the next step.
t. Grab an image (see the procedure for GRAB!).
2. Save the image in the catalogue C:WIy documents\Plaque\Test a  est.tif.
3. Export the image to Adobe Photoshop 3.0.
4. Press the Image mode - Qreyscale, and then 
'OK' on the mini-menu
Discard colour information?'
5. Delimit a 'black' area outside the B-mode picture on the screen with the
squared tool function, and press Image - flistogram. The mean value
should be between l-3. If it is <1 or >3, the 'BLACK LEVEL'-button on
the Panasonic 7650's 'TBC CONTROL' is hrrned a little
clockwise/counter-clockwise respectively, and the procedure is repeated
until the mean value is between 1-3 (but not 0, then the 'BLACK LEVEL'
is too low!). This procedure should be repeated at every start-up, and each
time a new videocassette is inserted, to ensure that background-black really
is black.
GRAB!
o Press Ctrl + M, or press the camera-icon in the menu (nr 6 from left) to grab the
image. Repeat until you have an optimal image. Every time Matrox Intellicam is
started, the 'Digitizer Confrguration Format' menu will appear on the screen - Choose
'PAL' in the box and press 'OK'.
o Save the image by pressing Alt+F'- A, or File - Save {s, (but not Ctrl+S, or Alt+F -
S, then the previous image will be erased!) and use the file name from the plaque
registration form. PS - checkfor writing error. The file is saved in the catalogue
corresponding to the tape number (Tape 0l etc...) under Tr4 or Tr5 respectively. (To
simpliff the hle name routine, the file can be copied from Excel, and pasted in the file
name column in Intellicam, and thereafter press <Enter> to save...but still check for
writing error!!). Fill in 'grab' - date (format: ddmmyy, f. ex 01 1102,150103) on the
Excel sheet as a 'receipt'.
o Wind on to the next plaque recording, adjust smoothly and repeat he
procedure... I I000 times!
Stein Harald Johnsen 2005
Trinn 1: Apne bildefit:
Trykk <F2>, uthev filen som skal brukes, og trykk
<ENTER>.
(Folgende skjer automatisk: Bildet dpnes i Photoshop,
gjores om til grdtoner, og lagres, deretter gjores
grdtone 0 pixler om til grdtone I pixler, og bildet
forstarres til 200Yo)
l 'J  tmo
f&Fd
s&F
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Folgende meny kommer opp:
Trykk <ENTER>
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Trinn 2: Finn GSM for lumen & adventitia:
LIIMEN: avtegn enten med 'Lasso Tool' eller 'Rectangular Marquee Tool' det omradet i lumen som:
. er msrkest/fri for stoy
. fortrinnsvis ligger i nrrheten av plakket
o Ved fargeopptak, mi et omrflde uten farge velges.
Trykk <Alt+I, H> for i fb frem histogram. Notdr median-verdien, og s6 trykk <Esc> for i f[ bort histogrammet.
ADVENTITIA: avtegn enten med 'Lasso Tool' eller 'RectangularMarquee Tool' et omride av adventitia som
r ligger mest mulig horisontalVvinkelrett il proben
. er i nrerheten av plakket (evt under plakket dersom dette er lysest og det ikke er skygge fra plakket)
. er lysest/har hoyest gritone
r omridet som velges skal vere ca0,25cmi bredde, og taes fra den indre (lumen-nare) halvdelen av
adventitia, og vil da utgjore minst 150 pixler.
Trykk <Alt+[, H> for ri f] frem histogram. Noter median-verdien, og si trykk <Esc> for i ffi bort histogrammet.
VIKTIG: ikke gior endringer pd bildet ftned <Ctrl+L>) i deue trinnet!
Protokoll for plakk-standardiserins
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Trinn 3: Foreta'ursve-standardiseringt:
Denne del-rutinen er for A teste hvorvidt GSM-verdiene fra lumen og adventitia gir 'riktige' GSM-verdier etter
normalisering. Lumen-GSM skal ligge mellom l-5, adventitia mellom 190-200. OBS: alle plahk skal
normaliseres, ogsd de med GSM verdier innenfor de definerte omrddene fer normalisering! Har bildet i
utgangspunktet GSM-verdier som er ncre opp til de definerte omrldene, kan Trinn 3 hoppes over, forsett med
Trinn 4.
Trykk <F4>
(Folgende skjer automatisk: Et fuplikat av bildet lages med nqvn 'Pr6ve', bildetforstanes til 200yo)
Menyen for innforing av 'input'-verdier kommer opp:
Fsr htn inn input verdie,ne (lumen i venshe boks, adventitia i
hoyre boks. Midtre boks skal ikke endres - md var,re |.0\
Trykk <Enter> eller OK
Folgende meny kommer opp:
Trykk <Enter> eller Continue, ettersjekk deretter GSM for lumen og adventitia.
o Onsher du nvfr forsek?
o Trykk <Ctrl*w> (vihi{!Dfor t fieme provebildet
o ta nye GSM milingerpi utgangs-bildet
o gjenta prosedyren ved i trykke <F4>.
. Onsker du ikke nvtt forssk?
o Fsr inn verdiene for hhv lumen- og adventitia-GsM brukt som grunnlag for standardiseringen.
o G[ videre til Trinn 4.
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Trinn 4: Avtesning av plakk, lagring av ikke-standardisert & standardisert fiI:
Trykk <Ctrl+w> (viktig!!) for i lerne provebildet, avtegn plakket med 
'Lasso Tool' (se kommentarer til slutt),
og trykk deretter <F6>.
f f i : i l
Folgende meny kommer opp:
Bare trykk <Enter> eller OK.
Ikke kooidr/lim fra Excel-filen her!
Fsr kun inn input verdiene (lumen i venslre boks,
edyentitict i huyre hoks. Midtre boks skal ikke endres - md
vere L00. Outputverdiene skal ikke endres)
OBS: alle plakk skal standardiseres, ogsd de med GSM
venlier innenfor de definerte omrddenefor
normalisering!
Trykk <Enter> eller OK.
Ulrrer lUilllltfiI
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Men pi neste meny kan PlakkFilNavn_0 hentes fra Excel-filen, og limes inn i feltet lame (hvor det default stAr'Untitled-l.tif ).
tr rii re
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Trykk deretter <Enter> eller
OK pi neste meny.
(Og dermed er det ikke-standardiserte plakk-bildet lagret! I neste stegfares input-verdierfor standardisering.)
Menyen for innforing av 'input'-verdier kommer opp:
1- s" l
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Kommentarer til Trinn 4: Avtegning av plakk:
-
Tips: dersom plakket er vanskelig i visualisere, kan man foreta en
tempor€r gri-skala fonkyvning ved i bruke 'Curves'-funksjonen
(<Ctrl+m>). Set pekeren over nedre venstre ende av linje, hold
venstre museknapp nede, og dra punktet horisontalt til hoyre. plakk-
bildet oppdateres automatisk. Husk i trykke <Esc> efler cancel, iv,ke
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Dersom plakket delvis ligge i akustisk skygge, skal kun de synlige deler av plakket avmerkes. Er plakket 'delt',
kan 2 eller flere omrider merkes med 'Lasso Tool'avtegnes iom vanlig ved A holde venstre museknapp nede
mens marksren merkes rundt plakk-delen. For avtegning av neste plakk, holdes <shift>-tasten nede og neste
omridet avtegnes med venstre museknapp. Er mindre en S|Yoau plukket'synlig', ekskluderes plakkei.
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Protocol - standardization of plaque
Software: Adobe Photoshop v7.0.1 .
Step l: Open image file:
Press <F2>, italicize the file of interest, and press
<ENTER>.
(Thefollowing occurs automatically: The image is
opened in Photoshop, transformed to gray levels, and
ssved. Then groy level 0 pixels are transformed to gray
level 1 pixels, and the image is blown up 2000/")
The following menu appears:
Press <ENTER>
HE-?Tffil itnp I
Step 2: Define lumen-GSM & adventitia-GSM:
LUMEN: Using the 'Lasso Tool' or 'Rectangular Marquee Tool' function, outline the lumen area which:
r Is darkest/without noise
o Is located near the plaque
r If the recording has been coloured , an atea without colour must be chosen.
Press <Alt+I, H> for histogram function. Mark the median-valuen and then press <Esc> to erase the histogram.
ADVENTITIA: Using the 'Lasso Tool' or 'Rectangular Marquee Tool' function, outline a part of the adventitia
which is
. as horizontal as possible/perpendicular to the probe
o located near the plaque (possibly under the plaque if this is the brightest part and without plaque
shadow)
r brightesV highest gray level
r the chosen area should at least have a width of 0,25cm, and represent he innermost (close to lumen)
half of the adventitia, and will then consist of at least I 50 pixels.
Press <Alt+I, fI> to have the histogram. Mark the median-value, and then press <Esc> to erase the histogram.
IMPhRTANT: Do not make ctny changes to the image (by <Ctrl+L>) at this stept!
-Finn 65lvt fr lsrcn a advenlitia. Fbtdr verdienel
-Fortsett deret{ef ved i trykke .:F4> fry I sjeld<e nffmatietrU}gen
-tlB5l - kke br* <Ctrl:.l
. l  *  r t r , *  F ! .
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$tpp 3: Do a'test-standardizationt:
This part is for testing whether the GSM-values from lumen and adventitia give 'the right' GsM-values after
strinrdardization. The lumen-GSM should be between l-5, adventitia between 190-200. PS: All plaques shoald
be standardized, incladlng those that ha'e GSM values within the predefined limit before standardizuion!
If the image has GSM-values close up to the predefined limits, then Step 3 may be skipped, proceed to Step 4.
Press <F4>
(Thefollowing occurs automaticolly: A duplicate of the image is creqtedwith the title 'Prove', the image is
blown up 200%0)
The msnu for inserting 'input'-values appean:
Fill in input values only (lumen values in the left box, adventitia
values in the right box. The box in between should not be
changed - must be 1.0)
Press <Enter> or OK
The f-ollowing menu appearc:
Press <Enter> or Continue.then check the GSM values for lumen and adventitia.
. ,
I o Do vou wsnt a new trisl?
o Press <Ctrl*w> Gmportant!!\ to erase the test image
i o Take new GSM measurements from the original image
o Repeat the procedure by pressing <F4>.
: .D@
. o Fill in the values for lumen- and adventitia-GSM that were used in the test standardization.
o Proceed to Step 4.
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Step 4: Outlinins of the plaque. savins the non-standardized & standardized file:
Press <Ctrl*w> $mpartant!!\ to erase the test image, outline the plaque using the 
'Lasso Tool' (see comments
in the end), and then press <F6>.
The following menu appsrs:
Press <Enter> or OK.
Do not copy/paste from the Excel-hle at this step!
f-l;F-t
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On the following menu PlaqueFileName_0 is copied from the Excel-fiIe, and then pasted in the box $ame (by
default titled'Untitled- I . tifl ).
-
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(And then the non-stqndardized plaque image is soved! In the next step the input-values for standardization are
filled in.)
'The 
menu for inserting 'input'-values appears:
Fill in inout values only (umen in the left box, adventitia
in the right box. The box in between must not be changed
- should be 1.00. The output values should not be
changed)
PS: all plaques should be standardized, including those
with GSM values within the predefined limits before
standardization!
Fress <Enter> or OK.
(The following occurs automatically: the standardized plaque image is soved with a new file name, and
Photoshop makes readyfor a new turn)
FINISHEDI
c zp r:k'rs sas.smgerrrE'
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CommenB to Step 4: Outlining of the plaqae:
Tip: If the plaque is difficult to visualize, a temporaxy gray-scale shift
can be performed using the 'Curves'-function (<Ctrl+m>). Place the
pointer over the left part of the bottom line, press the left mouse
button, and &aw the point horizontally to the right. The plaque
image is automatically updated. Remember to press <EsP or
Cancel,1g11 OK, to close the Curves-function!
If the plaque is partly located in an acoustic shadow, only the visible parts of the plaque shouldbe outlined. lf the
plaque is divided by the shadow, two or more parts of the plaque can be outlined with the 
'Lasso Tool' as usual
by pressing the left mouse button while the plaque is being outlined. When the next part of the plaque is !o be
outlined, press t}re <shifl>-key and then the plaque area is outlined by using the left mol$e button. If less than
50% of the plaque is visible, the plaque has to be excluded from analysis'
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